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Chapter 1 
SYSTEMS ANALYSIS IN PHARMACOLOGY 
1.1 INTRODUCTION 
The human body in itself is a very complex organization and it may be consid-
ered as a dynamical system. Its dynamical properties involve the selfcontroll-
ing aspects of the, from the outer world incoming signals, called input, the 
controllability of the actual state of the body, and the capabilities of con-
trolling its environment, either directly or indirectly. From this it is obvi-
ous that within the system a number of underlying control and decision pro-
cesses are involved such as the regulation of the basal temperature and the 
blood pressure, the light-dark adaptation of the eyes, the body movement con-
trol and so on. Most of these processes include linear or nonlinear feedback 
control mechanisms. 
Pharmacological in vivo investigations deal with the changes of the state of 
the body, caused by drug intake or exposure. As these state changes are sub-
ject to the drug input, they are usually referred to as the drug response or 
response function (Abraham 1983). Because the state of the body can be consid-
ered as a set of states, each being related with a different item of the body, 
it is obvious that the total number of states that can experimentally be 
observed, will be impractically high. Normally a subset of these states is 
defined for observation of the response on a drug application, dependent on 
the type of study. These subsets can be of various levels of complexity, e.g. 
behaviour protocols, bloodpressure, muscle tension, hormone concentration. 
From this it follows that state variables that are not part of the subset 
under investigation may influence the observed responses ; in this way errors 
can be introduced. 
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The above defined response function is a function which generally depends on 
time, the present state of the body and the input into the body, which can be 
more than only the drug input. Evidentally, the relation between the response 
function and the drug input may be highly nonlinear, so that it will be too 
difficult to be solved mathematically. Yet in order to be able to describe 
this complex relation some assumptions thereabout can be made : time-
invariancy, linearity or both. A system is said to be time-invariant if the 
response function does not depend on the time when the input is applied to the 
system. Linearity is an even further going assumption, which states that the 
réponse of a system to a linear combination of inputs equals the same linear 
combination of the responses of each of the related inputs. It can be shown 
that under both these assumptions there is a unique relation between the 
response function, the initial conditions of the body and the input into the 
body (D'Azzo and Houpis 1981). The initial conditions are the states just 
before the beginning of the experiiient and correspond of course with the sub-
set of states under investigation, e.g. the initial respiration frequency, 
erythrocyte productionrate, hormone concentration, etc. It can also be shown 
mathematically, that the unique relation can be described by a function, which 
has only a single argument : a time variable. This function is called the unit 
impulse response (UIR) or in a different form, the systems transfer function. 
From this it must be clear that knowledge of the UIR is essential in systems 
investigations. Once this function is known, one is able to predict what the 
response in time will be on a certain predefined input, with known initial 
conditions. In this thesis it shall be this crucial function that is subject 
to determination, clarification and further investigation. 
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1.2 PHARMACOKINETIC SYSTEMS ANALYSIS 
As in pharmacological sciences one is interested in the response of a drug 
dosage versus time, whatever nature this response may have, in pharmacokinet-
ics only one specific response is of particular interest, namely the amount or 
concentration of the drug or associated metabolites somewhere in the body. 
Basically, it is always possible to relate other types of responses to this 
drug concentration time function, although in many cases because of nonlinear-
ity, this relation can be rather difficult to determine. 
In general measurements of these concentration functions will not lead to the 
knowledge of concentration functions at other places in the body than the one 
at the sampling site. For several classes of pharmacokinetic processes these 
places may be experimentally unreachable or even vaguely defined, e.g. dru-
gabsorption and metabolite formation kinetics. Because detailed information 
about these processes can be rather useful, the concentration response func-
tions must be examined more closely. Usually for this the compartment model 
theory is used, but in this thesis this approach is not dealt with, although 
comments on its shortcommings will be made. 
When investigating pharmacokinetic response functions, the initial drug con-
centrations will often be zero. So from the response function, the influence 
of the initial conditions can be eliminated. Then the response is only deter-
mined by the input into the body in relation with the pharmacokinetic proper-
ties of the body. Assuming linearity, the input will have no effect on these 
properties, so then there is a unique and linear relationship between input 
and output, which for a given drug only depends on the pharmacokinetics of the 
body. 
Of course, linearity is only an assumption which might not seem realistic. But 
for many drugs and application sites the nonlinear contributions of several 
parts of the body are so small compared to the overall pharmacokinetic proper-
ties, that in these cases the body may be considered as a linear system (Hear-
on 1963, van Rossum et al. 1983a). 
Studying the kinetic properties of the body in more detail, these will depend 
on the properties of the organs and tissues, furtheron called subsystems, and 
the interconnections of these subsystems. Most subsystems receive the drug via 
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the arterial blood, called input, and after some time the drug will leave the 
subsystem with the venous blood, called output. Suppose that all drug mol­
ecules enter the subsystem at the same time (a unit impulse input), then 
because of stochastic processes, the molecules will leave the subsystem having 
different transit times. So, the unit impulse response is a density function, 
reflecting the frequency distribution of transit times. 
Since molecules may pass the subsystem immediately with the bloodflow, others 
may leave the bloodflow, enter cells and return later. Therefore the frequen­
cy distribution is drug dependent and specific for each subsystem. In fact the 
frequency distribution function actually reflects the transporting properties 
of the subsystem and will therefore be called transport function. So, the 
transport function of a subsystem is defined as a density function of transit 
times and it describes the transportation speed of the molecules, applied as a 
unit impulse, from the input to the output site of the subsystem (van Rossum 
1983b). 
1.3 LINEAR TIME-INVARIANT CONVOLUTION 
Although the transport function of a subsytem was defined using a very specif­
ic input, namely a unit impulse (an ideal bolus input), it is easy to see what 
the output will be for a different kind of input (fig. 1.1). Because an input 
function (versus time) can be thought of being composed of several bolus 
inputs one after another but possibly of different value, for each bolus the 
same reasoning as above can be applied. 
Ψ 
Fig. 1.1 The three related items in systems dynamics : the systems input 
function (I), its transportfucntion (ψ) and the systems output 
function (0). 
8 
So, the output of the subsystem is a linear addition of the output resulting 
from each bolus input function, but shifted in time as one bolus follows the 
other (fig. 1.2). This mathematical process is called linear time-invariant 
convolution (eq. 1.1) (D'Azzo and Houpis 1981, DiStefano et al. 1975). Note 
that in this case the transport function still characterizes the transport 
process completely : it neither changes for a different type of input function 
nor for the time the input function is applied. 
Transportfunction ь 
1 2 3 5 6 
Fig. 1.2 The principle of convolution : the input function (a) is a collec­
tion of bolus functions, which will be transported accordingly to 
the transport function (b), resulting in a contribution of the out­
put function (c). This is shown by marking each input bolus. 
Because of this feature, it is evident that knowledge of the transport func­
tion is very useful : for each input function, the output function can be pre­
dicted. Using Fourier or Laplace transforms, as will be done furtheron, the 
convolution equation then reduces to a simple form : the transformed output 
function is derived from the multiplication of the transformed input and 
transport function (eq. 1.2). 
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Because the transport function is a density function of transit times, its 
properties can easily be deducted from its functional shape (Churchill 1971, 
Papoulis 1965) : the area under curve (AUC) (eq. 1.3), which equals 1 if all 
molecules that entered the subsystem do leave that system on the output site, 
the mean (transit) time (MT or MTT) (eq. 1.4) (and modal or median time) and 
higher order moments which usually are of less importance. These parameters 
can also be derived from the transformed transport function (eq. 1.3b and 
eq. 1.4b) by applying the finite-value theorema (Churchill 1972, Yamaoka 
1978). 
Due to recirculations in the body, molecules may pass subsytems several 
times ; then the single pass time may not be very useful to deal with. More 
preferable will be the total time the molecules spend in a subsystem, which 
equals the mean single pass time for the subsytem multiplied by the mean num-
ber of recirculations. This mean time is called the mean residence time (MRT) 
for that subsystem and considering the body as a system, the same reasoning 
holds for the total body residence time. In these cases the transport func-
tion is not expressed as a density function of transit times, but rather as a 
density function of residence times. 
1.4 DETERMINATION OF A (SUB)SYSTEMS TRANSPORT FUNCTION 
Given a known input function (bolus, infusion, etc.) and a transport function, 
it is possible to calculate the output function on forehand using the already 
mentioned linear convolution equation. But as the transport function charac-
terizes the (sub)system, mostly one is interested in this function itself. To 
be able to determine this function, it is necessary to investigate the output 
function in time , which may be a concentration profile or dosage flow, 
resulting from a known input function. Then the mathematical inverse process 
of convolution, called deconvolution, can be applied to determine this func-
tion (eq. 1.5). As in the convolution equation the input and transport func-
tion are symmetrical to one another, it is also possible to determine an 
unknown input function given a known transport function. 
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It has already been mentioned that the application of a bolus input to a 
subsystem will result in an output function which is directly proportional to 
the transport function, with a correction for the amount of the dosage (unit 
dose). Note that this is only true if there is no other input to this system 
for instance via recirculation. So, this is an easy way to determine the 
transport function. For other types of inputs, the deconvolution process must 
be carried out. 
1.5 COMBINATIONS OF SUBSYSTEMS 
Two subsytems may be arranged in three different ways : in parallel, in series 
and in series with a feedback (positive or negative). More complex arrange-
ments as in the body, can (mathematically) be reduced to these three basic 
forms (DiStefano et al. 1975). 
The parallel case (fig. 1.3a, eq. 1.6a) : 
If two subsystems with different transport functions are connected in 
parallel then the overall transport function is the weighted mean of the 
two ; the weighting factor is the fraction of the total input flow for 
each of the systems. This also holds for the AUC and MT parameters. 
Two subsystems in series (fig. 1.3b, eq. 1.6b) : 
As the output function of the first subsystem is the input function of 
the second subsystem then accordingly to the convolution equation the 
output of the second subsystem is the convolution of the input function 
to the first subsystem and both transport functions. So the overall 
transport function of the two is then the convolution of the correspond-
ing transport functions. The AUC of the newly derived transport function 
is the product of the AUC's of both transport functions, while the over-
all MT is the sum of the two. 
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The positive feedback case (fig. 1.3c, eq. 1.6c) : 
If a system consists of two serial connected subsystems with a positive 
feedback, then the output function of the second subsystem will again be 
the (positive) input function of the first subsystem (Cutler 1981a, 
1981b). The resultant of the transport function will then be a repetitive 
convolution of the transport functions of the two subsystems, for each 
recirculation one repetition more. The output function of this system, 
which is defined to be the output of the first subsystem, will disperse 
for each recirculation progressively. In this case it is preferable to 
deal with the total mean residence time instead of a mean transit time. 
•*-o 
J · Φι 
ψ2 
о 
Fig. 1.3 Interconnections of subsystems : the parallel (a), the series (b) 
and the positive feedback case (c). The symbols Ι, ψ, 0 and f 
refer respectively to the input function, (the) subsystems trans­
port function, the output function and the fractional flows into 
the subsystems. 
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1.6 THE TOTAL BODY TRANSPORT FUNCTION (TBTF) 
The body is anatomically composed of mainly parallel subsystems receiving 
input from the serially connected heart lungs heart subsystems output and 
donating their output to the heart lungs heart input ; so, in essence it is a 
positive feedback system (fig. 1.4). 
Fig. 1.4 The total body systems model, composed of the most important subsy-
tems. This shows that the body is in fact a positive feedback sys-
tem. The symbols I and 0 refer respectively to the input and output 
functions in and from the defined reference points. 
To be able to describe the body as a system, one must define an input and out-
put site. As it is possible to apply an input via several ways (intravenously, 
orally, etc.) the drug will enter the bloodflow somewhere in the body, there-
fore the venous pool will be taken as a reference to this input (fig. 1.5). 
This is merely a choice for convenience and one may consider another refer-
ence ; with the aid of mathematical systems theory these two choices can 
always be related to one another. More difficult is the definition of the body 
output : the total set of the various metabolic and renal pathways are not 
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easily to determine. But because of its central role in the bloodflow, we take 
the heart lungs heart subsystem output as the body output reference point. All 
other possible outputs can then be related to this choice (fig. 1.5). The 
transport function of the body describing the transport from the input refer­
ence point to the output reference point is then defined and will be refered 
to as the total body transport function (TBTF). As the subsystems may be 
grouped together obtaining the resultant transport functions (fig. 1.5), one 
can even reduce the entire system to a simple three stage serial system. Log­
ically, the transport properties of the body depend on the TBTF and the choice 
of input site and output or so-called sampling site. 
Input 
transport Чф~ 
Heart/ 
Lungs 
Rest of 
the body 
Output 
transport 
TBTF ! 
Fig. 1.5 The total body systems model whereby the feedback subsystems are 
gathered in one subsystem. In this model the input and output func­
tion apply to other places in the body, but are related to the 
defined reference points by a corresponding transportprocess. The 
total body transport function (TBTF) will define the process for 
the entire positive feedback system and so the total transport sys­
tem is a concatenation of the three sequential processes. 
The TBTF, the transport function of a physiological arrangment of the various 
subsystems, is specific for each individual and it is crucial in the planning 
of a prescribed output function. Because for a known TBTF, it is possible to 
determine the input function for a required output function and further simu­
lation modelling can be applied how to achieve this, i.e. where the dosage 
must take place and in which amount (van Rossum 1971). 
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At this point a mathematical expression which describes the TBTF will be 
introduced (eq. 1.7). In this expression elimination of the drug is assumed 
not to take place in the heart lungs heart subsystem and the output function 
is the drug output flow of this same subsystem. The output flow is directly 
related with the concentration in the output reference point (i.e. aorta) by 
the cardiac output parameter. The dosage input function is, of course, the 
input into the reference point, which is by definition the vena cava. By 
mathematical manipulation, the AUG of the TBTF can be made equal to 1, revell-
ing the product of the cardiac output and the fraction being eliminated from 
the body at each circulation ; this product equals the total body clearance. 
From the expression it is also evident that the elimination fraction related 
with the mean number of recirculations will have a major effect on the mean 
residence time of the drug in the system. 
So, deconvolution of the concentration time function with the vena cava input 
dosage time function leads to the TBTF and the total clearance. 
1.7 SYSTEMS DYNAMICS VERSUS THE COMPARTMENT MODEL APPROACH 
In pharmacokinetic compartment model theory the body is assumed to be an 
arrangment of a number of interconnected pools in which the concentration of 
the drug is homogeneously distributed. The transfer of the drug between two 
compartments depends on the flow through the compartments, the total amount of 
drug in and the volume of the first compartment : a first order process (Bis-
choff and Dedrick 1968, Grodins 1963). On analyzing the effective drugflow 
between the two compartments, the result will always be a one or two exponen-
tial term, which strongly depends on both compartments (Riegelman et al. 1968, 
Eisenfeld 1979, Vaughan and Dennis 1979). In this way the whole model can be 
expressed mathematically, whereby its parameters can be optimized towards the 
measured concentration function. Using more compartments in the model, one is 
even able to describe this concentration more accurately, but the error in the 
parameters will increase rapidly and the physiological meaning of the model is 
loosing ground. As the parameters characterize the compartments, one must bear 
in mind that such an analysis does not validate the properties that are 
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attached to the individual compartments on forehand. So care must be taken 
when statements are made from this type of study about the properties of a 
single compartment. 
As the body can be thought of as a number of subsystems each having a specif-
ic, drug dependent transport function, the total kinetic behaviour of the drug 
in the body is a composition of the transport characteristics of each subsys-
tem. Thus, in systems analysis one deals only with (sub)systems with no 
assumptions about its contents. The scope here is how the speed of an incom-
ing (drug) flow is related with the outgoing flow. The function that relates 
these two is the transport function of the (sub)system and it can then be ana-
lyzed without bothering about how it can be mathematically modelled in a for 
that purpose suitable function (Rubinov 1971, Hearon 1972, Colburn 1981). 
Furthermore the number of parameters and the parameters itself used in com-
partmental analysis strongly depend on the chosen model, whereas the statisti-
cal parameters, which can be derived from a transport function directly, are 
model independent and thus easy to understand (Eisenfeld 1979, Chiou 1979). 
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Chapter 2 
A MODEL-INDEPENDENT DECONVOLUTION TECHNIQUE USING FOURIER 
TRANSFORMS 
2.1 INTRODUCTION 
The problem of linear deconvolution, i.e. the ill-conditioned nature of solu-
tions of the convolution equation, has been discussed extensively in the lit-
erature (Gamel et al. 1973, Valentenuzzi and Volachec 1975, Niemi 1976, Wil-
liams 1979, Di ffey and Corfield 1979). 
Several methods of deconvolution have been presented to counteract the problem 
of data noise sensitivity of the Unit Impulse Response (UIR), or so-called 
transport function (Cutler 1978a, 1978b, Veng Pedersen 1980a, 1980b, 1980c, 
1980d, Kiwada et al. 1977, Bassingthwaighte et al 1966, Kuruc et al. 1982, Loo 
and Riegelman 1968, Vaughan and Dennis 1978). Although Gamel et al. concluded 
the Fourier method to be severely error sensitive, this method is still very 
popular in various fields of linear and nonlinear systems investigations 
(Gardner 1963, Alderson et al. 1979, Hayden et al. 1983, Kemerait and Childers 
1972, Oppenheim et al. 1976). As Gamel et al. already denoted that smoothing 
procedures should be able to reduce the data noise sensitivity, a method based 
on Fourier transforms has been developed, extended with a least squares cubic 
spline data smoothing procedure. This method is set up because the problem of 
nonlinear systems identification, a future aim, can be solved applying higher 
order kernel calculations (Marmarelis and Marmarelis 1978, Lee and Schetzen 
1965), thereby making use of Fourier transforms. 
this chapter is submitted for publication in J. Pharmocokin. Biopharm. 
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Testing the error sensitivity of the new deconvolution method has been done in 
a slightly different way compared to the literature. Using repeated simula-
tions with random noise generators, together with the UIR its standard devia-
tion interval is calculated to obtain information about the local error sensi-
tivity. Also the UIR error distribution is calculated (Gamel et al. 1973, 
Kuruc et al. 1982) to obtain the weighted mean error sensitivity. In addition, 
it is possible to calculate a standard deviation interval of the UIR derived 
from experimental data. 
The method is tested by means of four different kinds of analytical UIR func-
tions, namely : 
1) a mono exponential 
2) a two exponential ( a revised form of 1) ) 
3) a polynomial 
4) a combination of an exponential and polynomial 
FUNCTIONVALUE-
DATASET 1 
INPUT 
OUTPUT 
zo 
15 
10 
05 
n-
I 
\ 
\ \ 
\ \ 
/ 
DATASET 2 
^ 
^~"---^^Trr 
DATASET ¿ 
Fig. 2.1 Functions used to test the deconvolution method (see table 2.1). 
Note the different time scale for dataset 4. 
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2.2 NUMERICAL TECHNIQUES 
Ζ.Z.I Numerical deconvolution 
In linear systems analysis the convolution integral equation (eq. 1.1) can be 
replaced by its Fourier transformed analogue (eq. 1.2). To deconvolve, one 
reverses equation 1.2 ; so it is possible to derive a system's UIR by, Fourier 
transforming both the output and input function, complex division and trans­
forming back to the time domain (eq. 1.5). The transformation is done using a 
numerical evaluation (eq. 2.2) of the transformation integral (eq. 2.1), most­
ly performed by a FFT algorithm (Cooley and Tukey 1965, Bergland 1969). 
A main obstacle is the constant time interval measurement necessary for the 
numerical Fourier transformation, especially when using pharmacological data 
(see also D'Argenio 1981). This obstacle can be bypassed using reliable inter­
polation schemes, although one should keep in mind that the highest time reso­
lution is determined by the smallest time interval measurement during the 
experiment. Cubic spline interpolation (de Boor 1978, Reinsch 1967 and 1971) 
is very suitable for this purpose, because the interpolation between two data 
points only depends upon other nearby data points, thus remaining the local 
functional form. Another advantage of interpolation is a better approximation 
of the numerical evaluation (eq. 2.2) of the transformation integral 
(eq. 2.1). The more interpolation points involved, the better the approxima­
tion, although in the end its effect will be negligible compared to the data 
noise. The upper limit is also determined by the computer program performing 
the Fourier transformation, whereby aliasing should be taken in account also 
(Marmarelis and Marmare!i s 1978). 
After deconvolution, the resulting function is smoothed using a least squares 
cubic spline function with variable knot loactions (Craven and Wahba 1979, 
Anselone and Laurent 1986, de Boor 1978) ; the advantages of this procedure 
have been discussed in the literature (Veng Pedersen 1980b, 1980c). 
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2.2.2 Testing procedure 
ι 
Output function 
data 
* 
© 
i 
Spline 
• 
FFT 
Random 
g e n e r a t o r 
Γ Input function 
data 
• 
Deconvolution 
P r o g r a m 
' 
Complex 
division 
1 
F F T " 1 
1 
S m o o t h e r 
Mean 
, 
1 
1 
1 
1 
θ 
1 
Spline 
i 
FFT 
L 
* 
Standard 
deviation 
1 
Fig. 2.2 The flow of the deconvolution method as a part of the main control 
flow, which is applied to determine the noise sensistivity of the 
UIR as a result of variations in both data input functions. 
To the data points of a prescribed input and output function a random number 
is added, generated from a normal distributed random generator ; its standard 
deviation is set relative to the value of the data point, analogous to previ-
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ously described methods (Veng Pedersen 1980d, Cutler 1978b, Kiwada et al. 
1977). After deconvolution the calculated UIR is stored. This process is 
repeated a hundred times, so one derives a mean UIR with its standard devia-
tion, revealing the reliability of the method presented. A flowchart of the 
whole test procedure including the various items of the deconvolution program 
are shown in figure 2.2. It is emphasized that each time a different set of 
random data is generated, in order not to be dependent on just one sample dis-
tribution, thus avoiding a systematic error in the sample distribution chosen. 
The calculated impulse réponses are compared with the corresponding true UIR 
and the UIR error is calculated (Gamel et al. 1973) in order to supply infor-
mation about the mean error and its distribution. Effects of parameter choices 
are discussed regarding the corresponding UIR errors and using the two-tailed 
Student t-test whereby these two different UIR error distributions are tested 
on significancy (p < 0.10). 
2.3 EXPERIMENTAL 
The data were generated from known input and response functions (fig. 2.1 and 
table 2.1). Random noise, normally distributed, was added to the exact data 
with a standard deviation of 0%, 1%, b% 10% or 20% of the level of the data 
points. For this purpose the pseudo normal random generator subroutine GGNPM 
derived from the FORTRAN IMSL library (IMSL 1982) was used, which is based on 
the polar method. A double precision FORTRAN program was written including 
some IMSL subroutines and including the complex division step ; this program 
is listed in chapter 10. The testing functions were interpolated to a total 
of 201 points in order to establish an appropriate time interval. This time 
interval was varied using also 26 (dataset 4 : 51), 101 and 401 points in 
order to study its effect on the ultimate result. Before Fourier transforma-
tion the function was extended using a least squares mono exponential func-
tion, thus preventing any discontinuity after the last data point (Nakamura et 
al. 1980, Childers et al. 1977). The total number of points chosen per func-
tion was 512 ; the effect of this extension was investigated using also a 
total of 256 and 1024 data points. 
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TABLE 2.1 Analytical input, output and unit impulse response (UIR) functions 
used to test the error sensitivity of the deconvolution method. 
DATASET 
1 
2 
3 
4 
SAMPLE TIMES 
0.1,0.2,0.3,0.4, 
0.6,0.8,1.0,1.2, 
1.4,1.6,2.0 
ibid. 
ibid. 
0.25,0.5.1.0,1.5, 
2.0,2.5,3.0,3.5, 
12.0,12.5 
TYPE 
UIR 
INPUT 
OUTPUT 
UIR 
INPUT 
OUTPUT 
UIR 
INPUT 
OUTPUT 
UIR 
INPUT 
OUTPUT 
FUNCTION 
1.2e-2t 
e "
5
^ 
1.2β-*-0.8β-Ζ*-0.4β-5* 
е
-
5
ч
е
-
ь 
1.2e-2t 
1.2e"t-0.8e"2t-0.4e"5t 
t<1.15 : 1.565*(l-t/1.15)2 
t>1.15 : 0.0 
е ^ Ч е ^ 
t<1.15 : 1.420t2-5.728t+ 
7.095-0.4409e"5t-6.654e"t 
t>1.15 : 
5.509е"5,>0.8212е"г 
te"1 
t2e-2t 
(t2+4t+6)e"2t+(2t-6)e"t 
After deconvolution, the smoothing process was performed using a least squares 
cubic spline data smoother with variable knots and working upon all data 
points involved. However the ultimate result was considered only to the last 
data point, not belonging to the extrapolated part : the 201st data point 
(resp. 26th (51st), 101st, 401st). The reason that a cubic spline data smooth­
er is chosen, is that it does not affect the lower order statistical moments 
of the function and that the knots can be placed in an logarithmic time scale, 
which suits very well for pharmacokinetic processes. 
The result at time t=0.0 was estimated during the smoothing proces, because 
the original result showed the left hand limit at time t=0.0, which is zero, 
instead of the right hand limit. The number of knots used was varied from 3 to 
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8 to find out their influence. It was not possible to calculate the optimal 
number of knots in terms of minimizing the least squares error, because in 
general the error decreased with increasing the number of knots. 
In all cases except dataset 4, the input function value at time t=0.0 was 
estimated using a least squares (poly) exponential extrapolation. The value at 
time t=0.0 of the input function of dataset 4 and the response functions of 
all datasets was set to zero with zero deviation, which is, of course, inher-
ent to the functions. 
2.4 RESULTS 
The reliability of the method presented will be discussed considering the cal-
culated mean UIR with its standard deviation bounds and the UIR error ; the 
former describing the local error sensitivity, the latter the weighted mean 
error sensitivity. Results are discussed in sequence of the parameters varied 
and the dependence on the DIR function type is regarded too. The parameters 
considered are : 
1) number of knots involved'in the smoothing procedure 
2) standard deviation of the noise generating function 
3) length of the least squares exponential extension 
4) timestep interval (i.e. number of interpolation points) 
2.4.1 Variation of the number of knots in the smoothing procedure 
As expected, increasing the number of knots generally leads to a diminishing 
stability ; this is shown by the slight increase of the standard deviation 
(fig. 2.3a-d) and the increase of the UIR error (table 2.2). However, the 
increase in the error sensitivity is not very dramatic, within the range of 4 
to 7 knots : 7.3 % - 10.0 %, 5.7 % - 8.2 %, 8.4 % - 11.3 % and 7.1 % - 8.1 % 
for resp. dataset 1, 2, 3 and 4. Results are plotted for the case of 5 knots 
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(fig. 2.4a-d). Using a too small number of knots may lead to a misestimation 
of the UIR (fig. 2.4h). 
DEVIATION 
0.30 
0.10 
0.03 
0.0H 
0.30-
0.10· 
0.03-
nm-
γ, 
\ ^ - . „ . . 
DATASET 2 
Χ 
0.30{ 
0.20 
0.10 
0 0.50 1.00 1.50 2.00 0 0.50 1.00 1.50 2.00 
0.15-1 
0.50 1.00 1.50 2.00 0 
TIME 
2.5 5.0 7.5 10.0 12.5 
Fig. 2.3 The effect of the number of knots used in the smoothing procedure 
on the standard deviation bounds. Depicted are the standard devia­
tions for the case of 4, 5, and 6 knots for all functions. Data 
noise on input and output function is 5%. Log scale for dataset 1 
and 2. 
24 
UIR-FUNCTIONVALUE 
25 5.0 75 100 125 25 50 75 10.0 125 
Fig. 2.4 Result of the deconvolution method for all test functions. Depict-
ed are the true UIR and its standard deviation interval. Data 
noise on input and output function is 5% (a-d) or 10% (e-g). The 
number of knots is 5 (a-d) or 3 (h). Log scale for dataset 1 and 2. 
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TABLE 2.2 Unit impulse response (UIR) error (in %) as a function of the num­
ber of knots used in the smoothing procedure. Data noise on input 
and output function is 5%, normally distributed. The number of 
intrapolation points of the input and output function is set to 
201, whereby the number of points in the extrapolation part is 311, 
except DATASET 4 : 55. 
CASE 1 DATASET 1 DATASET 2 DATASET 3 DATASET 4 
3 
4 
5 
6 
7 
8 
7.43±3.37 
7.32+2.97 
7.11±2.99 
8.72±3.68 
10.0+4.58 
11.7±4.65 
6.12±2.08 
5.72±2.22 
6.63±2.36 
6.83+3.11 
8.23+3.05 
9.06±3.48 
8.13+2.94 
8.40±3.16 
1 0 . Ш . 8 6 
10.9±4.03 
11.3±4.20 
13.2±5.17 
17.5±4.51 
7.13+4.24 
7.87±3.43 
7.87±2.54 
8.09±3.76 
8.61±3.88 
2.4.2 Influence of the noise level of input and output function 
TABLE 2.3 Unit impulse response (UIR) error (in %) as a function of the data 
noise level on input and output function. The number of knots used 
in the smoothing procedure is fixed at 5 and the number of intrapo­
lation points of the input and output function is set to 201 ; the 
total number of points in the extrapolation part is set to 311, 
except DATASET 4 : 55. 
CASE 2 DATASET 1 DATASET 2 DATASET 3 DATASET 4 
0 % 
1 % 
5 % 
10 % 
20 % 
0.91 
2.01±0.64 
7.11±2.99 
14.9±6.57 
27.9±12.2 
0.51 
1.62±0.47 
6.63+2.36 
12.4±4.84 
19.8±8.95 
1.26 
2.46±0.83 
10.1±3.86 
18.9±8.62 
31.9±14.3 
1.15 
2.59±0.38 
7.87±3.43 
13.8±7.04 
27.5±13.7 
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With no noise present on the input and output data the results show an UIR 
error between 0.5% and 1.3% (table 2.3) and a bias misestimation as shown in 
fig. 2.5. Increasing the noise level tends to a linear increase of both the 
UIR error and the standard deviation interval (figs. 2.4e-g). 
-0.01 
-0.01 1 1 г 
05 10 15 20 0 2.5 5.0 7^ 5 100 12 5 
Fig. 2.5 The bias misestimation of all functions tested when no noise pres­
ent on the data. 
All UIR errors are about of the same order as the chosen noise level, summed 
for both the input and output function. The mean UIR's show to be good estima­
tions of the corresponding true UIR's, although the polynomial of dataset 3 
could not be estimated very well at the constant zero level starting at time 
t=1.15 units ; i.e. a slight oscillating behaviour occurred. 
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2.4.3 Variation of length of the least squares exponential extension 
As one can see from table 2.4 the length of the least squares exponential 
extension has no significant effect on the UIR error for both datasets 2 and 
4. However, the UIR's of datasets 1 and 3 deviate significantly when the total 
number of points is 256 , i.e. when the extension part consists of 55 points 
(256 minus 201). This phenomenon can be explained by the fractional Area Under 
Curve (AUC) of the input function which is in case of datasets 1 and 3 and at 
time t=2.0 units only about 88.7 % of the total AUC ; in case of datasets 2 
and 4 this is 98.2 %. Extension with 55 points to a total of 256 points 
results in 93.5 % resp. 99.4 % of the total AUC and extension to a total num­
ber of 512 points in 99.5 % resp. 99.9 %. It is clear that too short an exten­
sion will result in a function value at the endtime which is not small enough 
compared to the function maximum and thus exhibiting the effect of a disconti­
nuity at the endtime. 
TABLE 2.4 Unit impulse response (UIR) error (in %) as a function of the of 
the number of points in the extrapolation part of both input and 
output function. The number of knots used in the smoothing proce­
dure is fixed at 5 and the data noise added on the input and output 
function is 5%, whereby the number of intrapolation points is 201. 
CASE 3 DATASET 1 DATASET 2 DATASET 3 DATASET 4 
55 8.83±3.67 6.62±2.05 11.5±4.33 7.87±3.43 
311 7.11±2.99 6.63±2.36 10.1±3.86 7.83+4.29 
823 7.85±3.06 6.55±2.31 9.07±3.14 7.60+2.82 
2.4.4 Variation of the timestep size 
Variation of the timestep size (Δι) shows that the use of too few intrapola­
tion points results in an increase of the UIR error (table 2.5) and a misesti-
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mation of the true UIR. This is most probably due to a worse numerical 
approximation of the Fourier integral. Increasing the number of points to over 
a hundred does not lead to further significant improvement. 
TABLE 2.5 Unit impulse response (UIR) error (in %) as a function of the num-
ber of intrapolation points on input and output function. The num-
ber of knots in the smoothing procedure is fixed at 5 and the data 
noise added on input and output function is 5%, normally distribut-
ed. The extrapolation length of the input and output function is 
also varied to obtain the same endtime in each case. 
CASE 4 
26 
51 
101 
201 
401 
DATASET 1 
10.2±4.92 
___ 
7.71+2.75 
7.11±2.99 
7.82+3.61 
DATASET 2 
7.75±3.20 
— 
6.88±2.18 
6.63±2.36 
6.76±2.26 
DATASET 3 
14.4±6.12 
—_ 
10.3±4.36 
10.1±3.86 
9.47±3.29 
DATASET 4 
— 
9.63+3.10 
7.97+2.75 
7.87±3.43 
8.64±3.65 
2.4.5 The choice of the UIR function type 
The error sensitivity of the ultimate result depends on the test function cho-
sen, as the UIR error varies within 3 % (table 2.2) with 5 % noise on input 
and output function. The polynomial of dataset 3 could not be estimated per-
fectly after t=1.15, due to the slight oscilating behaviour of the cubic 
spline data smoother. Dataset 4 could not be estimated well at time t=0.01 
this resulting from the extrapolation to t=0.0 during the smoothing procedure 
mentioned above. In cases if one expects, on theoretical grounds, to deal with 
this kind of functions, it is legal to constrain the original result at time 
t=0.0 which is 0.0, as stated before. 
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2.5 DISCUSSION 
Applying the model-independent deconvolution method as presented here, one has 
to chose the parameters mentioned before. Generally the ultimate result will 
depend on these parameters, but only slightly compared to the estimated data 
noise level. Keeping the following rules in mind, the result of a deconvolu-
tion calculation will certainly be very satisfactory in model-independent 
applications : 
a) Consider both input and output data ; the number of interpolation points 
chosen determines the accuracy of the Fourier integral calculation. 
Increasing the number of points tends to result in a greater accuracy but 
in the end will be negligible compared to the data errors. Results will be 
affected negatively using too few interpolation points. This can be inves-
tigated on forehand, for instance by calculating the AUC and mean residence 
time (MRT) of the concentration data as a function of the number of inter-
polation points. Routinely the number of interpolation points can be set so 
that, while increasing the number of points, the percentual fluctuation of 
the AUC and MRT is less than 0.1%. Generally, using more than 100 points 
will be satisfactory, but the ultimate result will not depend on it strong-
ly ; only the parameterization of the calculated UIR will deviate more from 
the true analytical outcome, due to the numerical approximation. 
b) The length of the least squares exponential extension part has to obey to 
the one and only rule that the chosen endtime must not have a strong effect 
on the AUC (i.e. <l%). Extending much too far may have consequences for the 
smoothing procedure, in particular for the choice of the number of knots. 
In addition, both the input and output function must have the same timestep 
size and the same total number of points, which is clear from the Fourier 
integral equation. Thus, together with the number of interpolation points, 
the choice of the two parameters will be obvious and numerically bound by 
the computer program limits (parameter n, eq. 2.2). 
c) The choice of the number of knots seems to be more result determining, but 
regarding to the standard deviation interval (fig. 2.3) its effect on the 
mean UIR is only small. A strong misestimation is possible if one choses 
too few number of knots, as can be seen from dataset 4 (fig. 2.4h and 
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table 2.2). However, no such a problem has to occur, for this will become 
clear comparing the result with its unsmoothed version (fig. 2.6). 
Dealing with an output function with a certain lag time, this function must be 
shifted over the lag time period, while, after deconvolution, this lag time 
has to be inserted in the calculated UIR (Game! et al. 1973). 
UIR-FUNCTIONVALUE 1 
0.5 
0.4 
0.3i 
0.2-
O/H 
0.01 
-0.1J, 
0.0 2.5 5.0 7.5 10.0 12.5 
TIME 
Fig. 2.6 Comparing an unsmoothed deconvolution result (dataset 4, 5% noise) 
with the smoothed result using 3 knots showing a misestimation at 
the tail part. 
Comparison with already existing deconvolution methods is not that straigth-
forward. Firstly, none of these other methods encompasses a calculation of the 
standard deviation bounds, neither iterativily nor analytically, which are the 
most direct indication for the error sensitivity. Secondly, in the method pro-
posed no function parameterization is needed, thus bypassing the problem of 
"how to fit the data" on forehand and afterwards. 
31 
UNSMOOTHED 
SMOOTHED (3 KNOTS) 
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Port 2 
Absorption kinetics 
34 
Chapter 3 
KINETICS OF THE INPUTFUNCTION 
3.1 INTRODUCTION 
It has already been mentioned in chapter 1, that, as far as the TBTF is con-
cerned, the input is referenced to the defined input place i.e. the vena cava. 
One can imagen that an application in this particular vein is generally too 
specific, so the question arises, what will happen with the body transport 
properties if another input place is chosen ? If one choses, say the arm vein, 
will that matter much ? Reminding the resulting transport function of two 
serially connected subsystems (chapter 1), this principle can then be applied 
in this case, whereby the first subsystem describes the transport of the drug 
from the actual input place to the vena cava and the second is the TBTF 
itself. As the overall transport function is then a convolution of the two 
subsystems, the new AUC is the product, and the MTT is the sum of the two. 
Thus the transport dependence on the choice of the application site can be 
described in terms of what happens with the AUC, i.e. will some drug be lost 
during the transport through the first subsystem, and with the MTT, i.e. how 
long does it take to transport the drug to the vena cava compared to the mean 
time the drug resides in the body (MRT). So, it is expected that the choice of 
the arm vein will not change the total body transport properties that drasti-
cally as for instance the oral application site might do. 
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3.2 ANALYSIS OF THE INPUT FUNCTION 
Dealing with input places that will have a measurable effect on the concentra­
tion output function, it is important to know how this initial transportpro-
cess, or so-called drug absorption can be described. 
ФаЬ5 Ψ 
Fig. 3.1 The systems model in case of an absorption input dosage D . , which 
is transported to the input reference point accordingly to ψ . and 
whereby the output function is the concentration function in the 
output reference point. 
For this purpose, the model of the serially connected subsytems is used 
(fig. 3.1). As the output concentration function is a convolution of the 
input function, the transport function of the first subsystem and the trans­
port function of the second subsystem (the TBTF), information about the over­
all transport function can be derived once the input function is known. Fur­
thermore, when the TBTF itself is known, one is able to derive the transport 
function of the first subsystem (eq. 3.1). Often it is not possible to have 
sufficient information about the input function (e.g. a tablet or capsule dos­
age), in that case one can still calculate the output function of the absorp­
tion process, which is of course the same as the input function to the second 
subsystem. The information held in that function is the drugflow resulting 
from the first subsystem and going into the systemic bloodstream : so it is 
the absorption input function. In compartmental analysis this absorption 
process is very often constrained to a mono exponential function including a 
time delay. As will be shown in the next chapter this might give rise to wrong 
interpretations of absorption processes. On the other hand, the new method can 
be used to investigate the absorption on forehand and then the absorption 
function thus calculated can be used to construct a more reliable model. 
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3.3 THE EXPERIMENTS TO DETERMINE THE ABSORPTION INPUT FUNCTION 
From the former paragraph it is evident that two experiments must be carried 
out : one to characterize the TBTF and one to determine the overall transport 
function of the two serially connected subsystems. To achieve this, a standard 
pharmacological crossover study has to be performed. The concentration meas­
urements following an intravenous dosage will suffice for the determination of 
the TBTF for this drug, thereby making the assumption that the input and out­
put places are "close enough" to the defined references (fig. 3.2 route a, 
eq. 3.2). 
Dabs- •-abs 
^V^a) 
Jabs 
Cabs 
Fig. 3.2 The systems model for solving either the absorption input function 
I , (t) or the absorption transport function0 , . The input func­
tion in the input reference point I. (t) results in an output con­
centration function C. (t) (route a) and an applied absorption dos­
age function D , (t), will ultimately result in an output 
concentration function С , (t) (route b). 
abs 
Consequently, the same output place should be used to sample the concentration 
output following the absorption input dosage. As in this absorption experiment 
the actual dosage input function may be undetermined, the absorption inputflow 
of the drug into the body input reference can be calculated from equation 3.3 
(fig. 3.2 route b). If in this equation the total body transport function and 
clearance are assumed not to vary between the two experiments, then elimina­
tion from equations 3.2 and 3.3 leads to an expression for the absorption 
input function (eq. 3.4). To prevent those variations, both experiments 
should be carried under the same conditions, or if possible at the same time. 
In case the applied drug input function is known, then with that function, the 
unknown transport function can be calculated from the already determined 
absorption input function accordingly to equation 3.5. Note that the transport 
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function calculated this way, has its input reference place where the dosage 
was applied. Evidently, its output reference place is the TBTF input refer-
ence. 
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Chapter 4 
CALCULATION OF THE THEOPHYLLINE ABSORPTION PROCESS FOLLOWING 
ORAL ADMINISTRATION 
4.1 INTRODUCTION 
Recently a crossover study has been published, describing the theophylline 
kinetics after p.o. and i.v. administration (Kaumeier et al. 1983). The aim of 
the investigation was the determination of the oral absorption process of Afo-
niluni (a theophylline tablet). This absorption process was characterized by 
the parameters bioavailability and τ , . In their investigation the authors 
fitted the plasma concentration data following i.v. administration to a bi-
exponential function and those following p.o. administration to a bi-
exponential (subjects 1-5) or three exponential function (subjects 6 and 7). 
The absorption process was calculated from the compartment analysis and so its 
parameters were constrained to a mono exponential function with a lagtime. 
In order to describe a (sub) process by model-dependent parameters, one has to 
investigate whether the process corresponds to the model. If not, the parame­
ters following from the model do not contain reliable information about the 
process. In this chapter the absorption input function is calculated, i.e. 
the drugflow coming to be available from the absorption process to the rest of 
the body as this mainly determines the plasma concentration level in time. 
Because no information is available from the dissolving process of the tablet 
itself, which in fact means that the applied oral input function is not known, 
it is not possible to calculate the absorption transport function of the drug. 
Variations in the absorption input function between individuals, will be an 
indication for the expected variations in the plasma concentration levels 
apart from the total clearance variability. So, for each individual this 
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absorption input function is determined using the deconvolution program 
(chapter 10) and the results are compared with the original. Then in this way 
it is possible to notice the deviation of the model-dependent from the model-
independent results. 
4.2 METHODS 
The original paper is referred to, concerning the theophylline experimental 
part of the research (Kaumeier et al. 1983), which will not be discussed here. 
The function of interest i.e. the theophylline input flow into the input ref­
erence point following an oral dosage, is derived from two different experi­
ments (fig. 3.2), as described in chapter 3. Firstly, the theophylline total 
body transport function (ψ(ΐ)) and V , are determined (eq. 3.2), using 
intravenous dosage : the concentration profile (C. (t)) is measured from this 
known input function, e.g. shot or infusion I. (t) (fig. 3.2, route a). Sec­
ondly, the unknown absorption input function I . (t) can be determined from 
the resulting concentration profile (C . (t)) (fig. 3.2, route b) and the i/i(t) 
and V -, already obtained in the former step. Thus I . (t), calculated from 
equation 3.4, is the result of both concentration functions С , (t) (eq. 3.2) 
dDS 
and С (t) (eq. 3.3), because I. (t) is known. I , (t) is normalized with iv ivv abs 
respect to the dosage amount and this function is also corrected for the intra 
individual differences in the tailpart of the plasma concentration profiles 
(eq. 4.1), which is the same as the original correction. 
The model-independent deconvolution method presented in chapter 2 has been 
applied to calculate the absorption input function. This deconvolution method 
originally encloses a smoothing procedure, which is disposed of in this inves­
tigation, because the results after deconvolution showed to be satisfactory 
accurate. 
In order to calculate the standard deviation of the absorption function using 
repeated simulations as has been done in the deconvolution testing procedures 
(chapter 2), the error in the original concentration data was estimated to be 
about 10%, normally distributed. 
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The concentration data were interpolated to a time interval of 2 minutes. The 
total endtime after least squares mono exponential extension of the concentra­
tion data is 2046 minutes. 
The bioavailability equals the AUC of the normalized absorption input function 
and it is calculated numerically (eq. 1.3). The mean time the molecules take 
to enter the central bloodpool following oral administration, the mean tran-
sittime or in this case called the mean absorption time (MAT), is also calcu­
lated numerically from the absorption input function (eq. 1.4). 
4.3 RESULTS 
The normalized absorption input functions are rate functions and they should 
be interpreted as the fraction (or percentage) of the total dosage applied 
orally that is transported from the absorption process into the central blood-
pool per time unit (minute). 
TABLE 4.1 The pharmacokinetic parameters of the theophylline anhydride (Afo-
nilum ) absorption process following oral administration : the 
peak absorption time (t ), the peak absorption (A ), the mean 
absorption time (MAT) and the bioavaiIbility (F) are calculated 
from the absorption input function. Parameters are given as 
mean ± standard deviation. 
Subject t „ A
m 3 v MAT F 
max max 
(min) (%/ππη) (min) (%) 
1 84±10 2.5±0.8 86.0±6.5 125+13 
2 16±5 2.6±0.5 49.0±3.6 90±7 
3 17±4 4.6+0.7 21.8+4.4 98±8 
4 16±5 8.3+2.3 16.9±1.5 103±24 
5 26±3 8.2±1.5 30.2±1.0 108±10 
6 8±1 23.2±3.3 7.7±0.6 109+12 
7 9±1 13.5+2.6 11.7±1.9 116±10 
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These functions are depicted in figure 4.1 and evidently, hardly any equality 
with a mono-exponential will hold. All functions show an initial increase of 
the absorption rate in time, reaching a maximum after some time which then is 
followed by a decline. The large interindividual differences are evident too 
and therefore it is useless to calculate a mean absorption input function from 
the seven functions. All parameters determined from the absorption input 
functions are presented in table 4.1 which shows that the peak absorption A 
varies from 2.5-23.2 %/min and the corresponding time t from 8-84 min ; the 
max 
MAT from 7.7-86 min and the bioavailability F from 90-125%. The uncertainty 
in the calculated absorption input functions is depicted as a standard devia­
tion interval, which show that the intra individual deviation is in the order 
of 5-25%; this applies also to the deviation of the MAT and bioavailability F. 
4.4 DISCUSSION 
The aim of the calculations is to compare the absorption process of theophyl­
line following oral administration with the model-dependent results. Although 
the model-dependent parameters resulting from fit procedures can be used to 
describe the plasma concentration curve adequately, they do not contain relia­
ble information about the absorption subprocess itself. The fact that none of 
the calculated absorption input functions correspond to a mono exponential but 
rather to a gamma function or set of exponentials, will confirm this. There­
fore the model-independent parameter MAT contains more reliable information 
than the model-dependent τ , and thus has more clinical value. 
abs 
The inter individual differences in the absorption of theophylline are quite 
obvious and have been noticed in the literature (Upton et al. 1982). This phe­
nomenon merely becomes evident in the initial rate of absorption. The expect­
ed relation with the total absorption time, i.e. the faster the initial 
absorption rate the shorter the time necessary to absorb all theophylline, is 
less evident. For some subjects there is a lag time, followed by a rapid 
absorption which ends quickly, while others having initially a rapid absorp­
tion, whereafter it decreases slowly. 
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Fig. 4.1 The input rate functions of theophylline for each subject, given as 
the percentage of the total dose applied orally, that enters the 
central bloodpool per minute, versus time (minutes). The uncer­
tainty (standard deviation) of the functions is shaded. Note the 
inter individual variability and the units on both axises. 
For this reason it might be useful to introduce a parameter which gives infor­
mation about the time necessary to absorb 50% of the applied dosage : the 
median of the absorption input functions. 
It should be noted that the problem that arises from the non parallel tail 
parts of both the С - and С . -time functions which is usually expected, is 
that one never knows if a correction for this should be applied. It is not 
unlikely that this phenomenon is a result of the absorption process itself. In 
case the decline of the С . -function is not as steep as the C. -function, the 
abs ^ iv 
explanation could be a very slow absorption rate. And in case the decline of 
the С , -function is significantly more than the one of the C. -function, this 
âDS IV 
could result from an effect of the applied absorption dosage upon the elimina-
tion process, which then is a noniinearity. 
Finally, it is emphasized that there is no significant difference between the 
bioavailabilities calculated by the method presented and the ones in the orig-
inal paper (Kaumeier et al. 1983). The reason for this is that the bioavail-
ability in the original paper is also calculated from model independent param-
eters and therefore there will be little or no deviation from the result as 
presented here. 
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Chapter 5 
THE ANTIPYRINE LIQUOR TO BLOOD TRANSPORT PROCESS IN GOATS 
5.1 INTRODUCTION 
The antipyrine transport from the lateral ventricle to the central bloodpool 
has been calculated by means of deconvolution from an intravenous and intra-
cerebral dosage. This type of calculation has been done, as it is an example 
of an absorption transportprocess. As in chapter 4, where an absorption input 
function is calculated, now it is even possible to determine the absorption 
transport function, because the applied dosage is known as a function of time 
(in fact an infusion). 
The characteristics of the antipyrine transport function could then be applied 
to observe more closely to the liquor to blood antipyrine exchange process, 
instead of implicitly assuming that this process can be described by a first 
order differential equation. 
5.2 MATERIALS AND METHODS 
5.2.1 Animal preparation 
African pygmy goats with a weight of 20-23 kg, were used for the 
intracerebral/intravenous crossover study experiments. The applied operation 
technique for the intracerebral experiments is described by Frens (1972) and 
Hecker (1974). Thereby the cannula was placed in the lateral ventricle and it 
was fixed on the head. 
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The cannulation technique for the intravenous administration, the atrium, and 
venous sampling, the aorta, was performed using a new type of cannula. A 30 cm 
silicon tube with a 1.98 mm inner diameter and 3.18 mm outer diameter contain-
S) 
ing a small needle (Medical-Grade Tubing, Silastic , Dow Corning, Michigan, 
USA), was pushed through the heart muscle or the aorta vessel wall. The two 
small pieces of perspex glued to the tube were used to attach the tube to the 
heart or aorta with Stiches. The tube was led under the skin to the neck and 
via a small incision in the skin, to the outerworld. The needle was withdrawn 
by means of a small twine attached to it and then the tube was filled immedi-
ately with a fysiological salt solution which also contained héparine. This 
technique was very successful and in this way hardly any blood was spilled. 
The volume of the canullae was determined, which should be taken into account 
while sampling. 
During the course of the experiments, the animals were not anaesthetized. They 
were then housed in an open cage, which just prevented them from walking away. 
The time interval between the intravenous and intracerebral experiments varied 
from 2-4 weeks. 
5.2.2 Chemicals, administration and sampling 
Antipyrine (OPG, Utrecht, the Netherlands) dissolved in ^ O was administered 
with a concentration of 50 mg/kg for the intravenous and 15 mg/kg for the 
intracerebral experiments. For both experiments this was done by means of an 
infusion of 30 minutes. For the intravenous experiments the administered vol-
ume was 19 ml, and for the intracerebral experiment this was 1.5 ml. 
One or two minutes after having started the infusion the first sample was tak-
en ; subsequent samples were taken with a 3 to 5 minutes interval during the 
first 45 minutes. The time the infusion ended extra samples were taken, with a 
1 to 2 minutes interval and furtheron with a 15 to 20 minutes interval. Sam-
pling continued up to 5 to 6 hours from the start of the experiment. After-
wards plasma was obtained from the blood by centrifugation and then the sam-
ples were stored at -15 degrees Celsius. 
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5.2.3 Antipyrine recovery from the plasma 
The procedure for antipyrine recovery from plasma using GLC has been described 
by Staiger (1980). Isopropyl-antipyrine was used as internal reference for 
the recovery : 50 μΐ i.e. 10 yg in water per 1 ml plasma. To this solution 
110 μΐ 5N NaOH was added to prevent antipyrine binding to the water layer. The 
drugs were extracted from the plasma using a 7 ml mixture of distilled ether 
and CH?C1_ (Merck) (2:1). The solution was mixed for 60 minutes and after­
wards the two layers were separated by centri fugati on for 15 minutes. The 
organic layer was transferred into another tube and it was evaporized under a 
gentle N~-stream at 35 degrees Celsius. The residual was dissolved in 35 μΐ 
ethanol and from this solution about 10% was injected in the gas Chromatograph 
(5710A Hewlett-Packard). The gas Chromatograph was equiped with a 
hL-detector ; the column length was 75 cm and it was packed with 3% carbowax 
20M -2% Κ0Η on gaschrom Q (100-120 mesh). 
5.2.4 The transport function of the absorption process 
The function of interest i.e. the antipyrine transport function from the lat­
eral ventricle to the central bloodpool, is derived from two different experi­
ments (fig. 3.2), as is described in chapter 3. The first experiment is used 
for the determination of the antipyrine total body transport function (ψ(ί)) 
and Si , (eq. 3.2), using an intravenous dosage : the concentration profile 
(C. (t)) is then measured from the known input infusion function I. (t) 
(fig. 3.2, route a). Secondly, the unknown absorption transport function 
Φ . (t) is calculated from the resulting concentration profile (C . (t)) 
dDS 3DS 
(fig. 3.2, route b), the known infusion input function D
 hc.(t), the antipyrine 
TBTF (Φ(ΐ)) and its total clearance (Ϋ-ι) the latter two obtained from the 
intravenous experiment. 
ψ . (t) can be calculated from equation 3.5 as a result of D . (t) and 
abs abs 
I . (t), whereby the latter is calculated from equation 3.4. For these calcu­
lations the model-independent deconvolution method has been used, which is 
presented in chapter 2. 
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In order to calculate the standard deviation of the transport function using 
repeated simulations likewise the deconvolution testing procedures (chap-
ter 2), the error in the original concentration data was estimated to be about 
10%, normally distributed. 
The concentration data were interpolated to a time interval of 1 minute. The 
total endtime after least squares mono exponential extrapolation of the con-
centration data is 511 minutes. The smoothing procedure was performed using 
5 knots. 
The bioavailability equals the AUG of the absorption transport function and it 
is calculated numerically (eq. 1.3). The mean transit time is also calculated 
numerically from the absorption transport function (eq. 1.4). 
5.3 RESULTS 
TABLE 5.1 The pharmacokinetic parameters of the antipyrine absorption process 
following intracerebral administration, calculated from the absorp-
tion transport function : the mean transit time (MTT) and the bioa-
vailability (F). Parameters are denoted as mean ± standard devia-
tion. 
Subject MTT F 
(min) (%) 
1 10.3+5.5 66±13 
2 11.3±5.2 78±13 
3 8.1±3.1 95±20 
4 8.5±4.5 92+17 
The absorption transport functions are rate functions and supply information 
about transportion speed from the liquor in the lateral ventricle into the 
central bloodpool. These functions are depicted in figure 5.1 The parameters 
determined from the absorption transport functions are in table 5.1 : the 
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b i o a v a i l a b i l i t y F varies from 66-95% (mean is 81%) and the MTT from 
8.1-11.3 min (mean is 9.5 min). 
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Fig. 5.1 The transport functions of antipynne for each goat, presented as 
the percentage of the total dose applied intracerebrally that is 
transported to the central bloodpool per minute, versus time (min­
utes). The uncertainty (standard deviation) of the functions is 
shaded. 
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The uncertainty in the calculated functions is depicted as a standard devia-
tion interval, which show that the deviation is in the order of 15-35%. For 
the bioavailability F the intra individual deviation is in the order of 20%, 
but for the MTT parameter this is 40-50%. The reason for this has to do with 
the behaviour of the absorption transport function which becomes negative for 
some time ; this will be discussed below. 
5.4 DISCUSSION 
The purpose of these experiments was to identify the absorption transport 
function of antipyrine from lateral ventricle to central bloodpool. As is 
shown, this process has a similar behaviour (fig. 5.1) as the test function 
dataset 3 in chapter 2 : the initial decline according to a second order poly-
nomial. This type of transportation indicates that the process cannot simply 
be described by a flow system, mathematically a first order differential pro-
cess. The reason for this could lie in the drug exchange mechanism between the 
liquor and the plasma. 
As occurred with dataset 3, i.e. a slight misestimation at the turnover point, 
this phenomenon might have appeared in the calculated absorption transport 
functions. This possible misestimation caused the functions to be negative 
over a period of time. It can also be explained from a nonlinearity caused by 
the intracerebral experiments. This nonlinearity would then have affected the 
extraction factor E (eq. 1.6), resulting in a systematic change in the total 
clearance. For this reason no correction has been applied to remove this phe-
nomenon from the transport functions from this occurence. 
The negative valued transport function also has its reflection on the bioaval-
ability and even more on the MTT (see table 5.1). So it should be stated that 
at least the MTT parameter will be unreliable and may as well contain a sys-
tematic error ; for the bioavailability this is less urgent because this 
parameter is not as error sensitive as the MTT. 
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Chapter б 
KINETICS OF METHYL ACRYLATE AND METHYL METHACRYLATE AFTER 
INTRAVENOUS AND EPICUTANEOUS ADMINISTRATION IN THE GUINEA PIG 
6.1 INTRODUCTION 
Acrylate esters are widely used in industry for the manufacturing of a great 
variety of polymers. Annual production of methyl methacrylate (MMA) in the 
western world was over 580 million kg in 1975 (IARC 1979a), while Japan and 
the USA produced together an estimated amount of 50 million kg of methyl acry­
late (ME) in 1976 (IARC 1979b). In addition to the bulk working up of acry-
lates with in general an adequate protection for the involved persons, there 
exists a diversity of end applications with a relatively unknown risk of expo­
sure. Examples of such applications are glues, textile finishes, dental fill­
ing materials, UV-curable inks and photopolymer coatings. 
Investigations on the metabolism of 1',C-MMA in rats (Bratt and Hathway 1977, 
Crout et al 1982) show an excretion of ^СО^ up to 88% of a single dose after 
oral or intravenous administration. As for methyl acrylate, the binding to 
sulfhydryl groups appears to be a major detoxication pathway in addition to 
oxidation to CO« (Seutter and Rijntjes 1981). 
Despite the fact that under occupational circumstances skin exposure is likely 
to occur frequently, no quantitative data are available with respect to the 
percutaneous absorption of these compounds. MMA is known to penetrate through 
rubber gloves (Pegum and Medhurst 1971, Waegemaekers et al 1983) and may give 
rise to serious side effects in humans (Fisher 1975). 
on mutual agreement this chapter is also a part of the thesis of 
T.H.J.M. Waegemaekers 
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So one of the main goals of the experiments presented here is to quantify the 
transportation process of acrylate molecules through the skin of guinea pigs. 
The characteristics of this process can be analyzed from acrylate concentra-
tion measurements after the epicutaneous dosage. Classically, based on a two 
or more compartment model, the concentration time functions can then be fitted 
to a set of exponential functions (Metzler 1969). In contrast to this approach 
the deconvolution method described in chapter 2 is used to calculate the acry-
late skin transportation process as a function of time. This type of calcula-
tion is already explained in chapter 3 as it is an example of the calculation 
of an absorption input function. Information such as the total fraction 
transported, i.e. bioavailability, and the mean absorption time (MAT) can 
then be derived from this input function. With the aid of this method it is 
possible to study the role of the skin as a barrier in the kinetics of MMA and 
ME. 
6.2 MATERIALS AND METHODS 
6.2.1 Chemicals 
Methyl (2,3-11,C) acrylate, specific activity 0.73 mCi.mmol and methyl 
(2-1''C) methacrylate, specific activity 0.347 mCi.mmol , were obtained from 
the Amersham Radiochemical Centre, England. (2,3-1',C) acrylic acid was pre-
pared by hydrolysis of methyl (2,3-1''C) acrylate in 0.15 M NaOH, followed by 
neutralization with concentrated HCl. The NaH^CO, was prepared by bubbling 
^COp through a 0.15 M NaOH solution. 
Analytical grade ethanolamine and 2-propanol were from Merck (Darmstadt, 
F.R.G.) and hexanol, triethylamine and dodecanethiol came from Aldrich 
(Beerse, Belgium). Soluene-350 and Instagel were obtained from Packard (Gron-
ingen, the Netherlands). 
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6.2.2 Animals 
Female Dunkin Hartley guinea pigs, 5-7 months old, weighing 550-750 g were 
obtained from the Broekman Inst. (Helmond, the Netherlands). Under anesthesia 
polyethylene catheters (inner diameter 0.58 mm, outer diameter 0.96 mm) were 
placed into the femoral artery and the jugular vein and led subcutaneously to 
the nuchal area where they went out of the body. The guinea pig was used for 
the experiment after recovery from this operation, which was assumed when her 
weight was at the pre-operation level. 
6.2.3 Experimental design 
During the experiments the animals were housed in all glass metabolism cages, 
designed to trap expired air and to separate urine from faeces. Food (Hope 
Farms, Woerden, the Netherlands) and water were provided ad libitum. Air was 
blown through the cage (volume 24 1) at a rate of 400 ml.min by means of a 
Verder Uni V-200 peristaltic pump, so the pressure inside the cage was some-
what lower than outside. This air was led through a train of gas-washing bot-
tles : the first one was empty and put on ice to trap expired water ; the next 
two bottles contained 5% (v/v) dodecanethiol and 2.5% (v/v) triethylamine in 
hexanol to trap unmodified acrylate and the last two bottles contained 20% 
water in ethanol ami ne (v/v) to trap expired CCL. 
Samples from these bottles were taken frequently via syringe-connected cathet-
ers without interruption of the air flow. The solutions in the bottles were 
exchanged for fresh ones at least 3 times in 24 hours. Urine and faeces were 
collected at 24 h intervals. The top of the cage was closed by a table-
tennisball, in which holes were drilled in order to pass through the catheters 
of the guinea pig. Blood samples were taken by connecting the arterial cathet-
er outside the cage with a syringe filled with heparin i zed saline and drawing 
the piston until the catheter was completely filled with freshly obtained 
blood. Then the connection was interrupted and by means of the heart pump the 
arterial blood dripped into a heparin!zed tube. When the required amount 
(0.1 ml) was collected, the catheter was again connected with the syringe and 
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the content of the catheter and 0.1 ml saline was injected again into the 
animal. 
6.2.4 Administration of the compounds 
For the intravenous application the radioactive compound, dissolved in 4ml 
saline, was administered via an infusion of 15 or 30 minutes into the jugular 
vein catheter. The amount remaining in the catheter was washed down with 
1.0 ml of saline. In these experiments the dose applied to each animal was for 
ME 0.092 mmol, for MMA 0.13 mmol, and for acrylic acid 0.15 mmol. 
For the epicutaneous administration, the left flank of the guinea pig was 
shaved and a glass cup, inner diameter 16 mm, outer diameter 24 mm, heigth 
10 mm was glued to the shaved skin with cyanoacrylate glue (Amycon's CY 2000, 
medium viscosity, Aldrich, Belgium) 18 hours before the start of the experi-
ment. The radioactive compound was injected undilutedly in the cup, which was 
closed immediately afterwards with a glass-cover with cyanoacrylate glue. 
Applied doses were 0.11 mmol of ME and 0.19 mmol of MMA. Elastic adhesive 
bandage of 7.5 cm width (Tensoplast, Smith and Nephew Ltd., England) was wound 
around the animal in such a way as not to hinder its respiration. 
In order to determine the residence time of ^CO- in the guinea pig body and 
in the metabolism cage, 3 additional experiments were carried out in which 
4 ml of a 0.15 M NaH^CO, solution was administrated in guinea pigs, not used 
before. 
At the end of the experiments the animals were killed by an intravenously 
injected overdose of pentobarbital (Narcovet ). 
6.2.5 Preparation for liquid scintillation counting 
Blood samples were fractionated in plasma and cells by centrifugation immedi-
ately after collection ; they were stored at 4 degrees Celsius for less than 
12 h. 
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Before removing the glass cup from the killed animal which was exposed epicu-
taneously, the cup was rinsed 3 times with methanol, then removed and rinsed 
again, 1 time with methanol and 2 times with petroleum ether. Rinsing fluids 
were collected in glass-scintillation vials until counting. The remaining 
activity in the cup was determined by heating the cup in a solution of potas-
sium bichromate (5% w/v) in concentrated sulphuric acid and trapping the pro-
duced ^COj in ethanolamine. 
The exposed skin was widely excised, cut into small pieces with scissors and 
solubilized in Soluene-350. 
Plasma, urine and washing-bottle samples were analyzed by direct scintillation 
® 
counting of weighted samples in Instagel . The ethanolamine samples required 
addition of methanol to obtain clear, homogenous samples. 
The faeces and the killed animals were stored at -20 degrees Celsius until 
counting. Of the exposed animals, lung, liver, kidney, spleen, heart and skin 
were assayed separately, brain and adrenals were also assayed in some animals. 
The remaining carcass and intestinal contents were homogenized. Faeces were 
also homogenized after addition of an equal volume of water. Quadruplicate 
weighed samples of the above mentioned tissues and excreta were dissolved in 
1 ml Soluene-350 and counted in 15 ml of an Instagel - 0.6 N HCl (9:1 v/v) 
mixture. 
Erythrocytes (0.040 ml) were dissolved in 1 ml of Soluene-350 - 2-propanol 
(1:1 v/v), bleached by addition of 0.3 ml H2O 35% (w/v) and counted in Insta-
Si 
gel - 0.6 N HCl (9:1 v/v). All solutions were counted in a Packard Tri-Carb 
3380 liquid scintillation counter. 
6.3 PHARMACODYNAMICAL ANALYSIS 
The function of interest i.e. the acrylate input flow into the central blood-
pool resulting from the skin absorption process, is derived from two different 
experiments (fig. 3.2), accordingly to the method described in chapter 3. 
Firstly, the total body transport function (TBTF) for the acrylates is deter-
mined (eq. 3.2), using an intravenous dosage : the concentration profile is 
55 
measured from a known input function, e.g. shot or infusion (fig. 3.2, 
route a). Secondly, the unknown input function after epicutaneous application 
(I u (t)) is calculated from the resulting concentration profile (fig. 3.2, 
route b) and the TBTF derived in the former step. The overall formula is pre-
sented by equation 3.4 and the Area Under Curve (AUC) and MAT parameter by 
equations 1.2 and 1.3 respectively. 
TABLE 6.1 Excretion of radioactivity in guinea pigs after administration of 
methyl ( 1',C)acrylate (ME), methyl ( 1',C)methacrylate (MMA) and 
('"CJacrylic acid (AA). 
Sub- Administration Urine ^CO- Exp. time 
stance route (% of dose) (% of dose) (hours) 
ME 
ME 
ME 
ME 
ME 
ME 
ME 
MMA 
MMA 
MMA 
MMA 
MMA 
MMA 
MMA 
AA 
AA 
intravenous3 
intravenous3 
b intravenous 
epicutaneous 
epicutaneous 
epicutaneous 
epicutaneous 
intravenous3 
intravenous3 
intravenous 
epicutaneous 
epicutaneous 
epicutaneous 
epicutaneous 
a intravenous 
intravenous3 
47.8 
48.2 
46.5 
32.6 
41.8 
31.6 
40.3 
9.7 
10.1 
11.3 
18.9 
15.9 
14.5 
19.5 
5.0 
5.1 
36.5 
36.3 
36.7 
39.8 
36.9 
46.0 
38.7 
69.7 
68.9 
66.5 
49.2 
55.4 
56.8 
57.6 
80 
78 
24 
24 
28 
28 
29 
39 
52 
24 
28 
24 
32 
60 
60 
60 
24 
24 
a) 30 Minutes and b) 15 minutes infusion. 
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Because not only the acrylate activity is detected in the plasma, but also any 
appearing metabolite activity, the model of figure 3.2 can not be applied in 
this case. In fact for all different types of metabolites a different TBTF is 
involved, which receives input from either the acrylate TBTF output site or 
from their precurors output site as will be explained in chapter 7. The new 
model is a composition of the various TBTF's of which the output refers to 
some
 1
'
,C-activity and all the outputs are to be integrated to one pool to be 
able to describe the total plasma-l',C measurements (fig. 6.1a). 
Ψ acrylate - · " metabolism 
Фсог 
cage - flow -»-Ceo· 
Fig. 6.1 The model that is used to determine the skin absorption from either 
the ^C-plasma measurements (a), or the ^CO,, measurements (b). 
In chapter 1 it has already been mentioned that combination of subsystems can 
easily be reduced to a single system which has the properties of all these 
subsystems. As can be seen from figure 6.1a, the model can be reduced to the 
configuration of figure 3.2, whereby the TBTF is the function which describes 
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the transport of ^C-acrylate from the input reference point to ^C-activity 
at the output reference point (see chapter 1). So far for the plasma measure­
ments ; in case of the CO- measurements some extra subprocesses are involved 
too, like the metabolization step from acrylate to ultimately CO-, the CO-
expiration process and finally the flow through the cage which is considered 
to be a first order process. All these processes are sequential and again it 
is not the well-defined output reference site the samples are taken from. So, 
the model as depicted in figure 3.2 has to be extended with those three sub-
processes to be able to describe the output reference point in terms of C0-
measurements (fig. 6.1b). But because for the same reason as just has been 
mentioned, those subprocesses can be thought of to be part of the central sub-
sytem, so the TBTF now stands for the transport of ^C-acrylate from input 
reference to 1',C0- at the cage output. As the flow through the cage is known, 
this subprocess will be eliminated from the 1 ЦС0_ measurements using deconvo-
lution, so the actual output reference will now be the expiration output site 
and the model of figure 6.1b also reduces to the one depicted in figure 3.2. 
6.4 RESULTS 
6.4.1 General 
For both acrylate esters and both ways of administration the excretion pat­
terns are shown in table 6.1, together with the results of the experiments 
with acrylic acid. For faeces, in all experiments less than 1% of the dose was 
excreted via this pathway. The total amount of radioactivity which remained 
in the body after termination of the experiment was measured in 10 animals and 
varied between 12% and 22% for both ME and MMA. Total recovery (mean±s.d.) was 
93.5±2.3% (n=6) for the epicutaneous experiments and 98.0±1.0% (n=4) for the 
intravenous experiments without significant differences between the 2 tested 
acrylates. 
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Table 6.2 presents the data of the organ counts. To correct for differences in 
exposure time and dosage, the results are presented in relation to the activi-
ty (dpm.mg ) of the homogenized carcass. 
TABLE 6.2 Range of radioactivity of organs relative to the activity of the 
carcass after epicutaneous (ec) and intravenous (iv) administra-
tion. 
Organ Methylmethacrylate Methylacrylate 
ec (n=3) iv (n=2) ec (n=3) iv (n=2) 
Carcass 
Skin 
Liver 
Lung 
Spleen 
Kidney 
Heart 
1.0 
1.0-1.1 
2.6-4.1 
1.8-2.2 
2.2-3.1 
3.0-3.4 
1.2-1.3 
1.0 
1.1-1.1 
2.3-2.3 
2.3-2.6 
2.7-4.2 
2.6-2.7 
1.2-1.2 
1.0 
0.6-0.6 
3.4-3.7 
3.2-3.5 
2.7-5.4 
3.8-4.4 
1.8-2.4 
1.0 
0.5-0.6 
3.9-4.1 
3.7-4.7 
2.9-4.1 
4.0-4.6 
2.8-2.8 
Brains and adrenals which only were counted in 2 animals dosed with MMA, did 
not show a higher activity than other internal organs. Upon intravenous admin-
istration 1.5+0.2% of MMA and 2.3±0.2% of ME was excreted unmodified. With the 
epicutaneous experiments it was impossible to distinguish between leakage from 
the cup and excretion from the animal. Since inhalation subsequent to leakage 
from the cup could interfere with the measured absorption, we only used the 
data from the epicutaneous experiments in which less than S% was excreted as 
unmodified acrylate. The part of the dose remaining in and on the exposed 
skin was considered not to have entered the animal and thus not included in 
the given dose. Table 6.3 shows which part of the total dose remained in the 
skin and on the skin. The exposed skin of the animals dosed epicutaneously 
with ME showed always gross signs of inflammation (edema, redening of the 
skin), while the animals treated with MMA did not show a visible change in the 
skin. 
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TABLE 6.3 Part of the dose of methyl acrylate (ME) and methyl methacrylate 
(MMA) that did not enter the systemic circulation in the epicutane-
ous experiments 
Sub- Skin Exp. time 
stance (% of dose) (hours) 
ME 
ME 
ME 
ME 
MMA 
MMA 
MMA 
MMA 
12.3 
9.1 
25.8 
8.2 
11.2 
6.3 
4.2 
8.1 
28 
29 
39 
52 
32 
60 
60 
60 
A significant amount of radioactivity was retained in the blood cells upon 
administration of ME. This cell bound radioactivity did not decline up to 10 
days after dosage. With intravenous administration the activity in the eryth-
rocytes only rose during the infusion and not afterwards, while in the epicu-
taneous experiments a much longer time (10-20 hours) was needed to reach the 
maximum radioactivity. MMA nor acrylic acid gave rise to the retaining of 
activity in the blood cells. Because of the apparent irreversibility of the 
binding of ME to blood cells we could compare the total amount of ll,C activity 
of these cells between intravenous and epicutaneous administration after cor-
rection for the total dose given. In this way we could determine the percent-
age of ME in the epicutaneous experiment, which reached the bloodstream in 
such a chemical form that it could bind apparently irreversibly to blood 
cells. For the intravenous experiments we found 5.6+0.3% of the dose in the 
blood cells (n=3), for the epicutaneous experiments (n=4) 4.2+0.4%, so it 
appeared that 75+11% of the dose passed the skin barrier unmodified. 
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6.4.2 Pharmacokinetic Results 
Primarily results will be summarized considering both CO- and plasma measure-
ments (table 6.4), because their discrepancy is responsible for the conclu-
sions that have been drawn. Thereafter the calculated absorption input func-
tions (AIF) are considered for CCL and plasma measurements (C0?-AIF resp. 
pl-AIF) per acrylate type ; the AIF's are truncated at that endtime which is 
the same as in the corresponding epicutaneous experiments. As total l'tZ activ-
ities are determined, no differentiation can be made between the acrylate and 
any appearing metabolites in the plasma. 
TABLE 6.4. Area under curve (ADC) and mean absorption time (MAT) parameters 
calculated from the CCL- and plasma absorption input functions 
(AIF), truncated (t)/ extrapolated (-), for methyl acrylate (ME) 
and methyl methacrylate (MMA). Also denoted is the time of the peak 
absorption of the corresponding AIF's : t . 
Sub-
stance 
ME 
ME 
ME 
ME 
MMA 
MMA 
MMA 
MMA 
co2-
AUCVAUC t ·> 
1.12/1.19 
0.97/1.15 
1.27/1.42 
0.88/1.08 
0.64/0.66 
0.56/0.77 
0.74/0.79 
0.78/0.87 
-AIF 
MAL/MAT 
t <» 
(minutes) 
574/671 
389/658 
840/1096 
730/1122 
761/787 
906/1432 
1204/1427 
1231/1615 
Plasma-AIF 
AUCVAUC t ·· 
0.89/0.96 
0.83/0.93 
a 
0.79/0.80 
a 
0.65/0.76 
a 
0.92/0.92 
MAT,./MAT t ~ 
(minutes) 
628/742 
510/774 
a 
1303/1308 
a 
854/1147 
a 
902/902 
max 
C02/pl-AIF 
(minutes) 
270/210 
200/ 30 
350/ a 
430/130 
440/ a 
570/910 
480/ a 
610/940 
a) : could not be determined because of too little samples in the epicutaneous 
experiment. 
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The CCL measurements of the bicarbonate experiments show an average mean tran­
sit time (MTT) for ^CCL of 67±2 min ; the MTT through the cage is calculated 
to be 60±5 min, resulting in 7±5 min for the ^CCL elimination from the guinea 
pig. In fact this is the mean transit time of CCL from the input reference 
point to the expiration output site. 
Because of the homogenity of the group concerning the intravenous results 
(table 6.1), the results are averaged for both the plasma and CO- measure­
ments. Before averaging, all the i.V. concentration time functions were nor­
malized to a unit bolus input function, hereby making use of deconvolution 
with the infusion input function. Analogous, from all 1I'C02 measurements the 
cage flow is eliminated by deconvolution of the original measurements with 
this first order process. 
Both methyl acryl ate (ME) and methyl methacrylate (MMA) intravenous experi­
ments show the same difference between the CO- and plasmacurves : the tail 
part of the latter decreases much slower compared with the former (fig. 6.2). 
% /MINUTE 
1.000 η, 
0.100-\ 
0.010-
0.001 -i . , 
0 8 16 7L, 32 40 0 θ 16 2U 32 ДО 
HOURS 
Fig. 6.2 The mean plasma and corresponding CO- total body transport func­
tions determined after intravenous application of a) methyl acry-
late (ME) and b) methyl methacrylate (MMA). These functions are the 
result of a deconvolution of the concentration profiles with the 
infusion input function, thereafter the functions are normalized so 
that the area under curve (AUC) equals 1. The function values are 
expressed as the fraction of the total dose that is eliminated from 
the central bloodpool ; the time axis is given in hours. 
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Fig. 6.3 An example of the plasma and corresponding CO» ^C activity in 2 
guinea pigs determined after epicutaneous application of a) methyl 
acrylate (ME) and b) methyl methacrylate (MMA). For the plasma data 
the dimension is DPM/50yl-plasma and for the CO« data this is DPM/ 
sec. 
ME and MMA epicutaneous experimental results show the same phenomenon as the 
intravenous results do : the plasma 1'fC activity decreases much slower com-
pared with the CO« measurements (fig. 6.3). Focussing upon the AIF's for ME 
(fig. 6.4) which are calculated accordingly to the model presented in figure 
3.2, the corresponding AUC's of the COp-AIF's vary from 0.88 to 1.27 (4 meas-
urements), derived from the truncated AIF. The AUC's of the pl-AIF's are cal-
culated from three experiments : 0.79 to 0.89. After mono exponential extrapo-
lation the AUC's are resp. 1.08 - 1.42 and 0.80 - 0.96, the former resulting 
in a bioavailability of more than 100%. The MAT varies from 389 - 840 min 
(CQp-AIF) and 510 - 1303 min (pl-AIF), after extrapolation resp. 658 - 1122 
min and 742 - 1308 min. 
In the case of MMA (fig. 6.5), the AUC's of the C02-AIF's and pl-AIF's are 
0.56 - 0.78 (N=4) and 0.65 - 0.92 (N=2) respectively ; after extrapolating 
0.66 - 0.87 and 0.76 - 0.92. The corresponding MAT's vary from 761 - 1231 min 
(COp-AIF) and 854 - 902 min (pl-AIF) and after extrapolation resp. 787 - 1615 
min and 902 - 1147 min. 
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6 4 The absorption input functions for methyl acrylate (ME) in 2 guinea 
pigs, calculated on basis of the CCL and plasma measurements. The 
function values are given as the fraction of the total dose applied 
epicutaneously that enters the central bloodpool The time is given 
in hours. 
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6 5 The absorption input functions for methyl methacrylate (MMA) in 2 
guinea pigs, calculated on basis of the C0 ? and plasma measure­
ments The function values are given as the fraction of the total 
dose applied epicutaneously that enters the central bloodpool The 
time axis is in hours 
6.5 DISCUSSION 
At the moment there is no "animal of choice" for studying percutaneous absorp-
tion (Wester and Maibach 1982, Bronaugh et al 1982). We chose the guinea pig 
for reasons of economy, easy handling, available experience on canulation of 
blood vessels and evidence that it is a reasonable animal model for this pur-
pose (Andersen et al 1980). 
The results of the intravenous administration of MMA to the guinea pig i.e. 
the rapid biotransformation to CCL are in good agreement with the results of 
Bratt and Hathway (1977) and Crout et al (1982), who applied MMA to rats. 
Together with other experiments in vivo (Delbressine et al 1981) and in vitro 
(Elovaara et al 1983), the available results may suggest a rather low potency 
of MMA to yield reactive metabolites. 
Markedly different from the excretion pattern of MMA is the one of ME, with 
much more activity in the urine (table 6.1). There is also a considerable pro-
duction of thioethers in the urine after administration of ME (Seutter and 
Rijntjes 1981), as a consequence of the direct Michael addition of ME to glu-
tathione (Delbressine et al 1981). Another indication for the nucleophilic 
character of ME is the apparently irreversible binding of ME to erythrocytes, 
a phenomenon which is also encountered with acrylom'trile (Ahmed et al 1982) 
and acrylamide (Miller et al 1982). In spite of this alkylating potency of ME 
compared to MMA, we found no difference in the percentage of the dose which 
remained in the body after termination of the experiment. 
Hydrolysis appears to be the major detoxification pathway of ME (Silver and 
Murphy 1981). Since acrylic acid did not bind to erythrocytes, we could deter-
mine the upper boundary of the fraction of ME which was hydrolysed in the 
skin : 25±11%. 
As shown in figures 6.4 and 6.5 and table 6.4, there is an unexpected discrep-
ancy between the acrylate absorption input functions calculated from the CCL 
data and on the other hand from the plasma data. This leads to the conclusion 
that the transport process of acrylate from guinea pig skin to central blood-
pool can not be modelled as it is in figure 3.2 (route b). Moreover, the cal-
culated functions will be an integration of a number of unknown processes 
among which is the acrylate skin transportation process. Although the number 
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of experiments is limited specially in the case of MMA, conclusions can be 
drawn. First we will discuss the intravenous experimental results (fig. 6.2), 
then the AIF-ME results (fig. 6.4) and afterwards the AIF-MMA results 
(fig. 6.5). 
Cpi 
*Cc02 
Fig. 6.6 The system model for both methyl acrylate (ME) and methyl methacry-
late (MMA). All boxes represent the transport processes of the mol-
ecules involved : input site and output site refer to the same kind 
of molecules or group of molecules. Formation of a (group of) 
metabol ite(s) is depicted as the input flow into a new transport 
process and originating from the transport process of its precur-
sor(s). Refer to the text for the meaning of the symbols. 
On the basis of the proposed system model (fig. 6.6), the conclusions will be 
discussed. At first the component F„ will not be taken into account 
(eqs. 6.1-6.5), but the results will show the necessity of its presence. All 
boxes depicted in the system model, represent the transport processes of the 
molecules involved : input site and output site refer to the same kind of 
molecules or group of molecules as it is defined in chapter 1. Formation of a 
(group of) metabol ite(s) is depicted as the input flow into a new transport 
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process and originating from the transport process of its precursor(s). The 
transport function for the acrylate will be called F,. 
The difference between the plasma and CCL intravenous results in both acrylate 
experiments can be explained by assuming an extra component in the plasma 
kinetics, which transport function in figure 6.6 is called F_. This component 
is additional to the plasma level and may be due to the very slow release from 
a binding site of the acrylate itself : from the literature it is known that 
ME and MMA have approximately the same binding constants with bovine serum 
albumin (Fujisawa and Masuhara 1980). 
The contribution of the ^CCL activity in the plasma is so small compared to 
all other components, that in all equations 6.1-6.5 its contribution has not 
been taken into account. Furthermore, the CO- clearance from the body is so 
fast (7+5 min.) compared to the acrylate clearance (several hours), that the 
influence of the CCL clearance on the total resuls will be neglected. Refer­
ring to table 6.4 the bioavailability resulting from the ME CO^-AIF appears to 
be more than 100%. So, a larger amount of 1' tC0 ? has been formed in the epicu-
taneous experiment relative to the intravenous experiment. As shown in 
table 6.1 the total '"CO- production seems independent of the acrylate infu­
sion rate, thus a saturation effect of the metabolizing system is not very 
likely. Then the bioavailability over 100% can be explained by the fact that a 
metabolite of ME must have been formed in the guinea pig skin (F.). Then from 
equations 6.4a, 6.4b and table 6.4 it follows that the partial C0?-clearance 
of F.. (Ε«,) will be less than the partial CCL-clearance of F. (Ε
η /,). 
From equations 6.3a and 6.3b it is evident that both AIF's are a sum of two 
different functions. The first function is the transport function of the skin 
itself and the second function is a convolution of this skin transport func­
tion with another complex function, which is composed of F., F ? and F. for the 
pl-AIF or F. and F. for the CO^-AIF. Then the difference in the peak time 
absorption of these AIF's (t , table 6.4) can be explained by the contribu­
tion of the very slow transport function in the denuminator of equation 6.3b 
compared to the one in 6.3a. These denuminators are directly related with the 
total body transport functions (eqs. 6.1a, 6.1b and fig. 6.2). 
As F ? is the transport function mainly responsible for the very slow decline 
in the plasma activity, its MRT will then be much larger than any MRT of the 
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other components. For this reason it cannot be explained from equations 6.5a 
and 6.5b, why the MAT on basis of the plasma measurements is larger the the 
MAT on basis of the CO« measurements. Therefore an extra component F, is need-
ed, which might either result from biotransformation in the guinea pig skin or 
from other components in the plasma. The one property that F, must have to 
explain the results, is a large MRT. 
The conclusions from the MMA absorption input function are in essence compara-
ble with those concerning the ME absorption input function, although derived 
differently. In all AIF-cases (on the basis of the CO- measurements) the 
bioavailability appears to be substantially less than 100%. So, metabolite 
formation in the skin can then also be the conclusion, which implies an extra 
component F-, analogous to the case of ME. 
The shift in the peak time absorption for the pl-AIF to the right from the 
C0„-AIF (see t , table 6.4) leads to a contradiction, when the same reason-¿ max 
ing as in the ME-case is applied here. So, the conclusion is that in the MMA 
system model another component F, must be included too. 
So, for both ME and MMA the equations 6.1-6.5 must be expanded with a compo-
nent F,, which because of the uncertainty about its origination, will lead to 
a wide variety of possible system model equations. For reasons of the limited 
number of experiments, it is not possible to extract the one and only correct 
set of equations and with those, the proper system model. Then the conclusion 
is that for both acrylates at least one type of metabolite is formed in the 
skin. 
The metabolite formation in the skin prohibited an exact determination of the 
permeationrate of the two tested acrylates through the guinea pig skin. On the 
other hand, it illustrates the need to take the metabolizing potential of the 
skin into account when assessing the toxicological behaviour of a substance. 
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Port 3 
Metabolite kinetics 

Chapter 7 
METABOLITE KINETICS AND SYSTEMS DYNAMICS 
7.1 INTRODUCTION 
As most drugs are transformed in the body into metabolites, the kinetics of 
these metabolites may be worthwhile to investigate, because for several rea-
sons. Firstly, the metabolite might have a significant pharmacological activ-
ity. Then it is very useful to be able to calculate the expected concentration 
level on forehand by means of simulations. Secondly, it might appear that the 
parent drug is very difficult to measure, which does not hold for its metabo-
lite. In this case the metabolite kinetics can be a good reference for the 
parent drug kinetics. 
Systems dynamics is very well suited to investigate these aspects, because it 
is only the relation between an input function, which can be the parent drug 
concentration function, and a corresponding output function, for instance the 
metabolite concentration function, that can be determined. Applying compart-
ment theory, analysis of metabolite kinetics is rather puzzling. Information 
needed about the relationship between parent drug and its metabolite are usu-
ally not available and thus a crossover study will result in pharmacokinetical 
'black-box' parameters. 
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7.2 THE SYSTEMS ASPECTS OF METABOLITE FORMATION 
The molecule transformation system is usually situated in the liver, which 
receives the parent drug with either the blood from the vena porta or from the 
liver artery. Because at each circulation through the system a fraction E 
(eq. 1.7) is extracted from the circulation, only a fraction (f M) hereof is 
transformed into the metabolite under study. Then as the output of the liver 
subsystem one may consider either the parent drug output flow or the metabo­
lite output flow. From this it is evident that the liver is the system that 
couples two transport systems which can be described independently and each 
with its specific TBTF : one that corresponds to the parent drug and one to 
its metabolite (fig. 7.1). So, the metabolite transport process is a specific 
kind of output function of the transport process of the parent drug (see 
figs. 1.5 and 1.6). Or the other way around, the parent drug output function 
as far as it is metabolized, is the input function into the metabolite trans­
port function. 
'par 'par 
M 
Ψ met 
•'par 
-"mei 
Fig. 7.1 The system model of metabolite formation. A parent drug input func­
tion I into the parent drugs TBTF (ψ ) will result in a parent 
par к э ^ р а г ' к 
drug output function (0 ). A fraction f M of this output function 
is metabolized by a metabolizing system M, of which the output 
function is the input function into the metabolites TBTF (ψ .) 
met 
resulting in a metabolite output function (0 . ) . 
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The metabolite output function can be described as the convolution of the 
parent drug input function, the parent drug TBTF, the fraction f M that will 
result in the metabolite under study, the metabolizing transport function and 
the TBTF of the metabolite (eq. 7.1). Although from this relation it should be 
possible to extract the characteristics of the metabolizing transport func­
tion, which are specific for each drug and individual, some remarks thereabout 
have to be made. At first the AUC of the metabolizing transport function 
equals 1, because it is defined that only a fraction f M that will enter this 
process is metabolized. Secondly, the mean time necessary to be metabolized, 
which is the MTT of the metabolizing system, is generally very short compared 
to the MRT's of both TBTF's. So, it is expected that the metabolizing trans­
port function will have very little effect on the metabolite concentration 
output function. In that case the system of figure 7.1 reduces to the already 
mentioned two serially connected subsystems and from equation 7.1 the function 
M can be deleted. 
7.3 ANALYSIS OF THE METABOLITE KINETICS 
From figure 7.1 (disregarding the metabolizing process), similarity with the 
problem of the determination of the absorption input and tranport functions 
which has been described in part 2, is evident. The TBTF of the metabolite 
can be determined in the very same way as in these absorption cases : an 
intravenous application I. . of the metabolite drug will result in a plasma K r
 iv,met э K 
concentration function С .(t) (eq. 7.2, fig. 7.2, route a). In case of an 
iv,met4 ' ч ч ' э ' ' 
intravenous application of the parent drug I. (t), this will then result K K
 ^
 э
 iv,par4 " 
in a plasma concentration function C M .(t) (eq. 7.3, fig. 7.2, route b). 
From equations 7.2 and 7.3 it is then possible to calculate ψ and the frac-4 r
 par 
tion f M (eq. 7.4) : this means that the clearance of the parent drug cannot be 
determined. 
As I
u
 .(t) is the input function into the metabolites TBTF, it can be M,met r 
derived from ψ .(t) and C
u
 .(t) likewise the absorption input functions 
met M,met 
described in part 2. 
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Once the parent drug concentration function C.
 D a r ( t ) is known, both the 
ψ (t) and its total clearance can be determined (eq. 7.5). So, f
u
 can be 
'par4 ' v M ' M 
calulated too (eq. 7.6) from equation 7.3, by elimination of ψ
 t (eq. 7.2) 
and ψ
ρ 3 Γ (eq. 7.5). 
iv, par 
(b) 
Краг 
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v, par 
'M 
&» 'met 
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Civ, met 
iv, met 
Fig. 7.2 The system model used in the crossover study. Application of an 
intravenous dosage flow of the metabolite I . results in a a
 iv,met 
plasma concentration profile С , (route a), supplying informa-v ν iv,met v ' r-h- ^  э 
tion about the transport function ψ ,. Application of an intrave-v
 met vv 
nous dosage flow of the parent drug I. will result in a plasma 
3 Y 3
 iv,par v 
concentration profile C. and after metabolization in a plasma 
concentration profile 0
Μ
 . (route b), revelling the metabolite v
 M,met v " 3 
input function I
u
 .. v
 M.met 
But it is then also possible to calculate the metabolites TBTF (ψ .(t)) 
met 
either from equation 7.2 or from equations 7.3 and 7.5. A mismatch between 
these two, will be caused by a nonlinearity, for instance in the metabolizing 
system. 
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Chapter 8 
A CROSSOVER ANALYSIS OF COTININE IN GOATS AFTER INTRAVENOUS 
ADMINISTRATION OF NICOTINE AND COTININE 
8.1 INTRODUCTION 
As previously reported (Benowitz et al. 1983), cotinine as a metabolite of 
nicotine is proposed to examine the nicotine intake process following ciga-
rette smoking. Nicotine kinetics are rather difficult to determine, because of 
the complicated analysis of nicotine and its fluctuative concentration in the 
human body during smoking (Griffiths 1982, Benowitz 1982, Turner 1975). On 
the other hand, the cotinine concentration is much more damped and the analy-
sis is far less troublesome (Benowitz et al. 1983). The cotinine kinetics fol-
lowing a cotinine dosage will lead to the TBTF of cotinine by means of decon-
volution. Also the cotinine kinetics following a nicotine dosage will lead to 
the cotinine TBTF once the nicotine kinetics have been determined. A mismatch 
between these two cotinine TBTF's will be an indication for a nonlinearity in 
either the nicotine, the cotinine or the metabolization kinetics. Consequent-
ly, cotinine kinetics will not be suitable for predicting the nicotine kinet-
ics. If no mismatch occurs the cotinine kinetics can be a good reference for 
studying the nicotine intake. 
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8.2 MATERIALS AND METHODS 
8.2.1 Animal preparation, administration of the compounds and sampling of 
the plasma 
African pygmy goats, weighing 16-18 kg, were used for the cotinine and nico­
tine experiments. The cannulae preparation for administration into the atrium 
and sampling from the aorta were carried out as is described in chapter 5. The 
time interval between the cotinine and nicotine experiments for each goat, was 
about 2-4 weeks. 
During the course of the experiments, the animals were not anaesthetized. They 
were then housed in open cage, which just prevented them from walking away. 
Nicotine (Merck, Hohenbrunn) dissolved in H ?0 was administered with a concen­
tration of 0.5 mg/kg, via an infusion of 30 minutes. The applied cotinine 
dosage (Medical University of South Carolina (prof. T.Darby)) was 2.5 mg/kg, 
also dissolved in hLO, and the infusion time was either 30 or 60 minutes. Both 
compounds were administered in a total volume of 19 ml. 
One or two minutes after having started the infusion the first sample was tak­
en ; subsequent samples were taken with a 3 to 5 minutes interval during the 
first 45 minutes and furtheron with a 15 to 20 minutes interval. Sampling 
continued upto 4 to 5 hours from the start of the experiment. Afterwards plas­
ma was obtained from the blood by centrifugation and then the samples were 
stored at -15 degrees Celsius. 
8.2.2 Recovery from the plasma 
Nikethamide was used as internal reference for the recovery of nicotine and 
cotinine from the plasma samples : 100 μΐ i.e. 200 ng in water per 1 ml plas­
ma. To this solution 0.75 ml 2N NaOH was added to prevent nicotine binding to 
the water layer. The drugs were extracted from the plasma using a 4 ml mixture 
of distilled ether and CHpCl- (Merck) (60:40) ; in case of the cotinine exper­
iments only CHpCl, was used. The solution was mixed for 1 minute and after-
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wards the two layers were separated by centrifugation for 15 minutes. The 
organic layer was brought into another tube and it was vaporized under a gen­
tle N?-stream at 35 degrees Celsius. The residual was dissolved in 35 μΐ etha­
nol and from this solution about 10% was injected in the gas Chromatograph 
(5710A Hewlett-Packard). The gas Chromatograph was equiped with a 
Ν,,-detector ; the column length was 75 cm and it was packed with 3% carbowax 
20M -2% KOH on gaschrom Q (100-120 mesh). 
For both nicotine and cotinine an oven temperature program was applied, which 
differed for both drugs. Temperature control started at 130 degrees Celsius 
for 2 minutes for nicotine or at 185 degrees Celsius for cotinine, then 
increasing with 4 degrees/min. upto 220 degrees Celsius for 2 minutes. 
It has to be noted that the used glassware for these experiments should be 
extremily clean. 
8.2.3 Kinetics of the cotinine TBTF 
For the system model of cotinine following from nicotine metabol ization, fig­
ure 7.2 and equations 7.2-7.6 can be used ; in these equations the various i/i's 
and corresponding total clearances apply to nicotine as being the parent drug 
and to cotinine as the metabolite. The metabolizing step from nicotine to 
cotinine is characterized by a process denoted by M and the fraction metabo­
lized by fM. In the crossover study, cotinine is applied intravenously with a 
known dosage flow I. ., resulting in a cotinine concentration profile 
С . (route a ) , thus deriving ψ .. Intravenous dosage of nicotine I. iv,cot v ' ' a 'cot 3 iv.nic 
results in a nicotine concentration profile С . o f which a fraction f
u
 of 
Γ
 ιv,nic M 
the nicotine extraction factor (E . ) enters the metabolizing system M, which 
transport process describes the conversion speed from nicotine to cotinine 
versus time. After this, cotinine is transported into the cotinine-TBTF ψ . 
of which the output function is the plasma concentration function C
u
 . r
 r^cot 
(route b). 
When no time variancy nor any noniinearity is assumed, then M and f M can be 
calculated from equations 7.1 using the nicotine and cotinine TBTF from the 
results of the crossover study. But when do taking time variancy and nonli-
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nearity in consideration, ψ . / SI , in equation 7.1 may not be replaced 
by ψ . / Si , . in equation 7.2, certainly not when both experiments are 
carried out at different times. 
In this investigation ψ . is calculated from equation 7.2 as well as from 
equation 7.3 whereby the nicotine TBTF is eliminated using equation 7.5. In 
the latter case ψ . will be denoted by ik. . to be able to distinguish both 
cot M.cot 
the cotinine TBTF's, derived directly and via the metabolizing route. Note 
that the metabolizing system in these equations is disregarded. The fraction 
of nicotine metabolized to cotinine, fM, is derived from equation 7.6 whereby 
both nicotine and cotinine TBTF's are eliminated from equation 7.3 using 7.2 
and 7.5 and assuming no change in Si , . , which will be discussed later. 
el ,cot 
So, now one is able to draw conclusions about the experimental variability 
and/or the influence of nicotine on the cotinine TBTF. In this way the conse­
quences for further crossover experiments can be studied. 
In order to calculate the standard deviation bounds of the TBTF's, thereby 
making use of repeated simulations, the uncertainty in the cotinine concentra­
tion data was estimated to be about lOfi and in the nicotine data 20%, normally 
distributed. The mean residence time (MRT) of the cotinine TBTF is calculated 
accordingly to equation 1.4. 
8.3 RESULTS 
The parameters Si , . , Si , . and f
u
 are listed in table 8.1 whereas 
el ,mc el ,cot M 
MRT(</J ) and MRT(ik, ) are listed in table 8.2 the calculated functions 
ψ .(t) and ψ« .(t) and the corresponding standard deviations are depicted 
'cot4 ' rM,cot v ' r 3 v 
in figure 8.1a-d, for each goat separately. 
The nicotine clearance S¡ . varies from 0.66 to 1.27 l/min with a mean of 
e I,nic 
0.92 l/min. The cotinine clearance Si . varies from 0.13 to 0.28 l/min, 
el ,cot 
whereby the mean is 0.21 l/min. The fraction nicotine metabolized to cotinine 
varies from 0.27 to 0.57 (mean is 0.38). 
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TABLE 8.1 The cotinine and nicotine clearances, 9 , . resp. У , . , cal­
culated from the cotinine and resp. the nicotine plasma concentra­
tion measurements following from the corresponding intravenous 
experiments. The fraction of nicotine metabolized to cotinine, fM, 
is derived from equation 7.6. Parameters are given as 
mean ± standard deviation. 
Εχ
Ρ·
 V
el,cot 'el,nie fM 
(1/min) (1/min) 
1 0.28+0.02 1.27+0.17 0.21+0.05 
2 0.28±0.02 1.01±0.14 0.40+0.07 
3 O.mO.01 0.75±0.08 0.28+0.06 
4 0.23±0.01 0.66±0.08 0.57±0.10 
For goat 1 two nicotine experiments have been performed (experiment 1 and 2 
resp. figure 8.1a and b), which lead to a different result for fM : 0.21±0.05 
and 0.40±0.07, for V , . : 1.27±0.17 1/min and 1.01+0.14 1/min and for 
e ι ,mc 
ΜΚΤ(ψ
Μ
 J : 21.6±4.1 min and 29.7+5.9 min. 
г
М,со^ 
TABLE 8.2 The mean residence time (MRT) of cotinine, calculated from the 
total body transport function (TBTF), following from a cotinine 
dosage (ψ ,) and from nicotine administration (ψ
ω
 . ) . Parameters 3 ч
 cot' M,cot' 
are given as mean ± standard deviation. 
Exp. MRT-*
cot M R T - 4 c o t 
(min) (min) 
1 17.0±1.3 21.6+4.1 
2 17.0±1.3 29.7±5.9 
3 27.9±1.5 31.6±5.4 
4 22.Oil.9 31.2+4.5 
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Comparing ψ .(t) with ψ
Μ
 (t) and the corresponding parameters for all 
experiments, the MRT of the latter is somewhat longer : mean 22.3 min resp. 
28.5 min. This is also expressed in the initial decline of the two calculated 
functions of which the latter is less steep. 
% / MINUTE 
100.0 Η 
10.0-
100 0 
10.0-
® 
'M WITH NICOTINE 
120 0 
MINUTES 
Fig. 8.1 The total body transport functions for each goat (a-d), calculated 
from equation 7.2 (cotim'ne i.v. experiment) and from equation 7.3 
(nicotine i.v. experiment) are depicted in the form of its standard 
deviation bounds (shaded area). Both results are in the same figure 
for comparison. The function values are expressed as the percentage 
of the total dose that is eliminated from central bloodpool per 
minute. The time axis is given in minutes. 
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8.4 DISCUSSION 
The idea of setting up the experiments was to check the variability of the 
cotinine TBTF either resulting from a cotinine dosage or from a nicotine dos­
age. In order to perform a reliable crossover study, in terms of trying to 
gain information about the nicotine absorption process resulting from cotinine 
measurements, the TBTF consistency is an absolute necessity. Situations where­
by intra individual variabiltity of the plasma concentration patterns becomes 
evident, or whereby the cotinine clearance and/or distribution is affected by 
the presence of nicotine can be a reason for inconsistency. In that case a 
crossover analysis may give rise to false interpretations. When the nicotine/ 
cotinine application is given at the same time, time-variancy will be elimi­
nated, but noniinearities might still occur. 
The inter individual variability in both nicotine and cotinine clearances, 
V , . resp. Ϋ , ..is obvious, whereas from experiment 1 and 2 the intra 
e I ,mc el ,cot 
variability is noticed also. This is also true for the fraction of nicotine 
metabolized to cotinine, fM. 
f M Is derived from equation 7.6, assuming no variability of the cotinine 
clearance under influence of nicotine. So, any inter experimental fluctuation 
of V
 η
 . causes an equivalent uncertainty in f
u
. An alternative for the cal-
e] ,cot M 
culation method of f M could be a least-squares fit of equation 7.3 to equa­
tion 7.4, whereby the sum of squares is minimized with respect to ψ .(t) : in 
this way the uncertainty in the ί , . parameter can be circumvented. 
The MRT of both ψ
 t(t) and ψ Μ (t) (table 8.2) in conjunction with the ini-
tial fall of the corresponding TBTF's reflect a systematic difference 
(figs. 8.1a-d). This difference seems not very crucial, but it occurs in all 
tested goats. If it is assumed that the metabolizing process M(t) is not very 
fast compared to the TBTF's, these findings can be explained by the influence 
of M(t), which was ignored in the calculation. If not, the conclusion can be 
drawn, that the presence of nicotine has at least some influence on the coti­
nine elimination. 
Though the number of experiments is limited and performed on goats, the incon­
sistency of the cotinine TBTF merely in the initial phase has become evident. 
This has consequences for the crossover study of nicotine and cotinine in 
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order to determine the nicotine absorption following cigarette inhalation. So, 
it is proposed that this study should be performed under more stable condi-
tions, whereby cotinine is applied at the same time as nicotine, but in a 
labelled dosage form. 
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Chapter 9 
EQUATIONS 
O(t) J i(t-e) ·ψ(θ) άθ Ξ I(t)*\Kt) 
Ο(ω) = Ι(ω) · φ(ω) 
АиС
ф
 = ƒ iD(t) dt 
AUG = lim ψ(ω) 
ΜΓ
ψ
 = { ƒ t'Ut) dt } / Αυο
ψ 
0(t) : outputfunction 
I(t) : inputfunction 
ψ(ΐ) : transportfunction 
ω : Fourier transform variable 
AUG. : Area Under Curve of ψ 
Ψ 
MT = -lim { !^1η(ψ(ω))} } 
ω+ο 
W. : Mean Time of ψ (i.e. 
MTT Mean Transit Time, 
MRT Mean Residence Time or 
MAT Mean Absorption Time) 
4i(t) = F 1 { 0(ω) / Κω) } 
F : inverse Fourier transformation 
operation 
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1.6a ψ(ω) = ί ^ ^ ω ) + f ^ C u ) ) 
AUG, = f,AUG, + f„AUG, 
Ψ 1 Ψ1 2 Ψ2 
кг
ф
 = í^m^
 + £2Аис
ф
 т
ь 
b ψ(ω) = φ ^ ω ) · Φ2(ω) 
AUG, = AUG. AUG, 
Φ Ψ1 $2 
MT. = MT, + MT. 
Ψ Ψ 1 Φ 2 
s t 
с 1 - pass : ОДсо) = Ι(ω) · ψ, (ω) 
2 - pass : Ο (ω) = Ι(ω) · ψ.(ω) · Ψ2(ω) · ψ,ίω) 
th Ы-1) 
η - pass : 0 (ω) = Ι(ω) · ψ.(ω) · { φ.(ω) · Φ2(ω) } ,näl 
sum of all passes : £ 0.(ω) = Ι(ω) · ψ(ω) 
i=l 1 
and : Φ(ω) = ψ^ω) / { 1 - Φ^ω) · Φ2(ω) } 
AUG, = AUG, / { 1 - AUG, AUG, } 
Φ ^і ^і ^2 
MRT, = MT. + AUG, AUG, · { MT. + MT, } 
Φ Ψ1 Ψ 2 φ
 L
 Φ 1 Φ 2 > 
1.7 С(
Ш
) = ^ - · 1(ω) · φ(ω) . ^ r V 
el 
φ(ω) = Ε · Π(ω) / { 1 - (1-Е) · Η(ω) · Γ(ω) } 
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V ι : total clearance 
el 
V_ : cardiac output 
E : fraction extracted from the 
bloodflow each circulation 
Η : transportfunction of the 
heart-lungs-heart subsystem 
F : transportfunction of the 
rest of the body 
2.1 ψ(ω) = Í iKt)-e іш1 dt 
2.2 ψ(1<Δω) = At · { I iKmAt) · e"i(kAu>)(lnût)},0Sk<n ,η=2π/(ΔωΔί) 
3.1 C(ü>) = ¿ - · В
а Ь 8( Ш) · Ф а Ь £ > ) · φ(ω) 
el 
D : absorption dosage input­
function 
ψ , : absorption transportfunction 
the TBTF 
3.2 С. (ω) = J^- · Ι. (ω) · ψ(ω) 
ιν V , ιν 
el 
3
·
3 с
аь 3
( ш )
 = ττ ' ^ 3 ( ω ) ' ψ ( ω ) 
el 
С. : concentration function after 
ιν 
intravenous input 
I. : intravenous inputfunction 
IV 
С , : concentration function after 
abs 
absorption dosage inputfunction 
absorption inputfunc 
the reference point 
I , : absorption inputfunction in 
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3 Λ
 W » - hi™ ' { С а Ь з ( ш ) / C i v ^ ) } 
3
·
5
 Ф
а
ь 8
( и )
 = hbs™ I Dabs<W> 
A.l I . (ω) = ( D. /D . ) · ff С , (ω) · F ( e " t / < : ' r e l , i v ) )} / 
ans iv abs' \ L absv ' v / J 
{ Civ(<ü) · F ( e " t / ( ' r e l , abs ) )}1 
F : Fourier transformation 
operator 
τ , . : time-constant of the tail-
el, iv 
part of the intravenous con­
centration function after 
fitting 
τ
 λ
 , : idem, for the absorption 
ej., aDs 
concentration function 
, F.Cco) 
6 Л а С
І ,СО 2(Ш> - V - ' ' Í ^ B · f 1 ^ 0 1 } 
F,(ω) Ρ,(ω) 
b CiV,pl^ = \^ '
{ \ ^ fl"V~+ f 2 ^ r ) } 
6
-
2 a C
e c . C 0 2 ^ ) = Dec ' [ ^ ' \^) ' { ^ ( f j ^ - E o ! ) + ^ \ ^ Ά Λ 
f ι F,(ω) F (ω) F,(ω) j 
b C
e
c , P l ( ^ = D e c * [ \ ' F s ^ ' Í f 0 ( f l ^ - + f 2 ^ + f 4 - Î ^ >) 
f F,(ω) F (ω) ì 
6.3a МТ
С0Ы) = F s ( U ) £ 0 + ΡΒ(ω) · [{ f 4 ^ - E 0 4 } / Í f f - ^ O l }J 
f F,(ω) F (ω) F (ω) , 
b ΑΙΡ
ρ1(ω) = F s ( U ) £ 0 + F g ( U ) · [{ f,^— } / { f , — + f2 j — }J 
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f + f/ f Ж ι / χ f Ж ι] r 0  l 4 E. > ' l I I Ε
η
 J v
 4 1 
f0 Λ{^\} l { h\ + f2T-2 ^} 
MTT
s
 + ί ψ- { -kMRT^-MRTp + ^(MRT4-MST2) }] / 
( { ( | ) г
 + (^) 2}AUC p l 
»
f0 + f4 = ! 
.fj + f2 = 1 
F. : transportfunction of com­
ponent i 
E. : extraction factor of com-
i 
ponent i 
E-. : extraction factor of com-
Oi 
ponent i, which is trans­
formed to CO« 
s : skin 
f
n
 : original acrylate fraction 
available from the skin 
absorption 
f. : fraction of original acry­
late which does not bind 
to plasma 
¡2 '• fraction of original acry-
late which binds to plasma 
f, : metabolite fraction formed 
4 
in the skin 
7.1 С,. „(ω) = Д · Τ (ω) · { ψ (ω) / Ε } · f
u
 · Ε · Μ(ω) Tl.raet ν_ parv ' L раг ' par ' M par v 
7.2 ψ (ω) = î ,
 н
 · { С. „(ω) / Ι.
 ν
(ω) } 
met el,met l iv.met iv.met J 
7.3 ψ (ω) = V , ,. « ^ і · { С
м ь
(ш) / Ι. „(ω) } / ψ (ω) 
met el.met fM
 ι
 M,met ' iv.met ' раг / 
7.Α ψ „(ω) = ^ і- · { Ο, „(ω) / С. „(ω) } / { Ι (ω) / Ι. (ω) } par4 fM ι ^l.met iv.met4 / ' L iv.par iv,metv ' ' 
7.5 ψ (ω) = tf , · { С. (ω) / Ι. (ω) } 
par4 el,par l iv.par4 iv,parv ' ' 
7.6 fM = =,—^  · { Q, „(ω) /С. (ω) } / { С. ,(ω) / Ι. „(ω) } M V L T4,met4 ' iv,parv ' > l iv.met4 ^ iv.met4 ' J 
el.par r ' 
ψ _ : metabolite transportfunction 
met p 
ψ : parent drug transportfunction 
С.. : metabolite concentration M.met 
after metabolization of the 
parent drug 
C.
 t : metabolite concentration iv,met 
after intravenous dosage of 
the metabolite 
C. : parent drug concentration iv,par r " 
after intravenous dosage of 
the parent drug 
I. . : metabolite inputfunction iv,met r 
after intravenous dosage of 
the metabolite 
I. : parent drug inputfunction iv.par K B ' 
after intravenous dosage of 
the parent drug 
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fM : fraction of the parent drug 
metabolized to the metabo­
lite under study 
Μ(ω) : Fourier transformed metabo-
lization transportfunction 
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Chapter 10 
THE FORTRAN-DECONVOLUTION PROGRAM 
С 
С > MAIN : VERSION 1.2, DATE 17-MAY-1984 
С programmer : HANS BURGERS 
С 
С FILE I/O : 
С 
С TERMINAL INPUT - UNIT 5 
С TERMINAL OUTPUT - UNIT б 
С ERROR OUTPUT - UNIT 7/6 
С OUTPUTFUNCTION READING - UNIT 10 
С TRANSPFUNCTION READING - UNIT 11 
С INPUTFUNCTION WRITING - UNIT 12 
С 
С IMSL-ROUTINES : VSRTRD, VSRTUD, IQHSCU, ICSEVU, FFT3D, ICSVKU 
С OTHER EXTERNAL ROUTINES : CLEAR (CLEARS THE TERMINAL SCREEN) 
С 
С INITIALIZE SYSTEM PARAMETERS TO DEFAULT 
CALL INITAL 
С GET PARAMETERS FOR DECONVOLUTION AND FUNCTIONS TO BE DECONVOLUTED 
CALL GETDAT 
С PERFORM THE DECONVOLUTION OPERATION 
CALL DECONV 
С RESULT MAY BE SMOOTHED / ROUTINE FOR EXTERNAL USE 
CALL SMOOTH 
С SHOW AND STORE RESULTS 
CALL PUTDAT 
С PROGRAM EXIT UNDER NORMAL CONDITIONS 
STOP 
END 
С 
С > INITAL : 
С 
С 
SUBROUTINE INITAL 
С DECLARATION 
IMPLICIT REAL*8 (A-H,0-Z) 
CHARACTER*8 ANSWER 
LOGICAL*! TERMIO.SMOPER 
С COMMON 
COMMON /SYSUSE/ lERR.LNITRM.LNOTRM.LNERRO, 
1 LNOFNC.LNTFNC.LNIFNC,TERMIO.SMOPER 
С 
С INITIALIZE LOGIC UNIT NUMBERS 
LNITRM=5 
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LN0TRM=6 
LNERR0=7 
LN0FNC=10 
LNTFNC=11 
LNIFNC=12 
IERR=0 
10 CONTINUE 
С READ FROM STACK YES OR NO FOR INTERACTIVE MODE 
READ (LNITRM,1000,END=20) ANSWER 
IF (ANSWER .EQ. 'YES') THEN 
С SET INTERACTIVE MODE ON 
TERMIO=.TRUE. 
LNERRO=LNOTRM 
ELSE IF (ANSWER .EQ. 'NO') THEN 
С SET INTERACTIVE MODE OFF 
TERMIO=.FALSE. 
ELSE 
GO TO 10 
END IF 
RETURN 
20 CONTINUE 
CALL ERRHND 
GO TO 10 
С 
1000 F0RMAT(A8) 
END 
С 
С > GETDAT : 
С 
С 
SUBROUTINE GETDAT 
С DECLARATION 
IMPLICIT REAL*8 (A-H,0-Z) 
LOGICAL*! TERMIO.SMOPER 
С COMMON 
COMMON /FIDATA/ TIMOUT(1024),FNCOUT(1024), 
1 TIMTRP(1024),FNCTRP(1024), 
2 TIMINP(1024),FNCINP(1024), 
3 NUMOUT.NUMTRP.NUMINP 
COMMON /SYSUSE/ IERR,LNITRM,LN0TRM,LNERRO, 
1 LNOFNC, LNTFNC, LNIFNC JERMIO, SMOPER 
С 
С READ TRANSPORT-FUNCTION FILE, MAXIMUM 1024 ELEMENTS 
NUMTRP=1024 
CALL RDFILE(LNTFNC,TIMTRP,FNCTRP,NUMTRP) 
IF (IERR .NE. 0) THEN 
IERR=1 
CALL ERRMSG 
END IF 
С READ OUTPUT-FUNCTION FILE, MAXIMUM 1024 ELEMENTS 
NUMOUT=1024 
CALL RDFILE(LNOFNC,TIMOUT,FNCOUT,NUMOUT) 
IF (IERR .NE. 0) THEN 
IERR=2 
CALL ERRMSG 
END IF 
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С GET DELTA-T AND ENDTIME PARAMETERS, ALSO SMOOTHING IS INVOKED 
CALL GETPRM 
RETURN 
END 
С 
С > DECONV : 
С 
С 
SUBROUTINE DECONV 
С DECLARATION 
IMPLICIT REAL*8 (A-H,0-Z) 
LOGICAL*! TERMIO.SMOPER 
COMPLEX*16 CMPLWK,FRQOUT,FRQTRP,FRQINP 
С COMMON 
COMMON /WORK/ CMPLWK(l),FRQOUT(1024),FRQTRP(1024),FRQINP(1024), 
1 REALWK(6294).INTGWKC6294) 
COMMON /FIPARM/ DLTTIM,ENDTIM,NUMELM,NUMSPL,NUMEXT 
COMMON /FIDATA/ TIMOUT(1024).FNCOUTÍ1024), 
1 TIMTRP(1024),FNCTRP(1024), 
2 TIMINP(1024),FNCINP(1024)> 
3 NUMOUT.NUMTRP.NUMINP 
COMMON /SYSUSE/ IERR,LNITRM,LNOTRM,LNERRO, 
1 LNOFNC,LNTFNC,LNIFNC,TERMIO,SMOPER 
С 
IERR=0 
С PREPARE THE TRANSPORT-FUNCTION FILE 
С I.E. INTERPOLATION, EXTRAPOLATION AND FREQUENCY TRANSFORMATION 
CALL PREPAR(TIMTRP,FNCTRP,NUMTRP,FRQTRP) 
IF (IERR .NE. 0) THEN 
IERR=3 
CALL ERRMSG 
END IF 
С PREPARE THE OUTPUT-FUNCTION FILE 
С I.E. INTERPOLATION, EXTRAPOLATION AND FREQUENCY TRANSFORMATION 
CALL PREPAR(TIMOUT,FNCOUT,NUMOUT,FRQOUT) 
IF (IERR .NE. 0) THEN 
IERR=4 
CALL ERRMSG 
END IF 
С CALCULATE INPUT-FUNCTION SEQUENCE, DIVISION IN THE FREQUENCY DOMAIN 
CALL DIVIDE 
IF (IERR .NE. 0) THEN 
IERR=5 
CALL ERRMSG 
END IF 
С TRANSFORM INPUT-FUNCTION BACK TO THE TIME DOMAIN 
CALL TRTIME 
RETURN 
END 
С 
С > PUTDAT : 
С 
С 
SUBROUTINE PUTDAT 
С DECLARATION 
IMPLICIT REAL*8 (Α-Η,Ο-Ζ) 
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LOGICAL*! TERMIO,SMOPER 
С COMMON 
COMMON /FIDATA/ TIMOUT(1024),FNCOUT(1024), 
1 TIMTRP(1024),FNCTRP(1024), 
2 TIMINP(1024),FNCINP(1024), 
3 NUMOUT.NUMTRP.NUMINP 
COMMON /FIPARM/ DLTTIM,ENDTIM,NUMELM.NUMSPL.NUMEXT 
COMMON /SYSUSE/ lERR.LNITRM.LNOTRM.LNERRO, 
1 LNOFNC,LNTFNC,LNIFNC.TERMIO,SMOPER 
С 
С CLEAR SCREEN IN INTERACTIVE MODE 
IF (TERMIO) CALL CLEAR 
С GET NUMBER OF ELEMENTS IN INPUT-FUNCTION 
С CHECK IF EXTRAPOLATION IS INVOKED 
NUMINP=MIN0(NUMSPL-1,NUMINP) 
DO 10 IVAL=1,NUMINP 
С WRITE TO DISK 
WRITE(LNIFNC,1000) TIMINP(IVAL),FNCINP(IVAL) 
С AND TO TERMINAL IN INTERACTIVE MODE 
IF (TERMIO) WRITE(LNOTRM,1000) TIMINP(IVAL),FNCINP(IVAL) 
10 CONTINUE 
С CLOSE INPUT-FUNCTION FILE 
ENOFILE LNIFNC 
С AND REWIND INPUT-FUNCTION FILE 
REWIND LNIFNC 
RETURN 
1000 F0RMAT(2D13.5) 
END 
С 
С > RDFILE : 
С 
С 
SUBROUTINE RDFILE(LUNIT,TIMVAL,FNCVAL,NUMVAL) 
С DELARATION 
IMPLICIT REAL*8 (A-H.O-Z) 
LOGICAL*! TERMIO,SMOPER 
DIMENSION TIMVAL(NUMVAL),FNCVAL(NUMVAL) 
С COMMON 
COMMON /SYSUSE/ lERR.LNITRM.LNOTRM.LNERRO, 
1 LNOFNC,LNTFNC,LNIFNC,TERMIO,SMOPER 
С 
IERR=0 
С STORE MAXIMUM NUMBER OF ELEMENTS ALLOWED TO BE READ 
MAXVAL=NUMVAL 
С READ-IN SEQUENCE 
DO 10 IVAL=1,MAXVAL 
READ (LUNIT,*1END=20) TIMVAL(IVAL),FNCVAL(IVAL) 
10 CONTINUE 
С MAXIMUM ALLOWABLE ELEMENTS READ 
IVAL=IVAL+1 
20 CONTINUE 
NUMVAL=IVAL-1 
С TEST ON MAXIMUM NUMBER OF SAMPLES TO BE READ (WARNING MESSAGE) 
IF (NUMVAL .GÈ. MAXVAL) THEN 
IERR=4 
ELSE 
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С IN CASE OF END-OF-FILE 
REWIND LUNIT 
END IF 
RETURN 
END 
С 
С > SRTFIL : 
С 
С 
SUBROUTINE SRTFIL(TIMVAL,FNCVAL,NUMVAL) 
С DELARATION 
IMPLICIT REAL*8 (A-H.O-Z) 
COMPLEX*16 CMPLWK.FRQOUT.FRQTRP.FRQINP 
DIMENSION TIMVAL(NUMVAL),FNCVAL(NUMVAL) 
COMMON 
COMMON /WORK/ CMPLWK(l),FRQOUT( 1024),FRQTRP(1024),FRQINP(1024), 
1 REALWK(6294),INTGWK(6294) 
С 
С IMSL-PROCEDURE 
DO 10 IVAL=1,NUMVAL 
INTGWK(IVAL)=IVAL 
10 CONTINUE 
CALL VSRTRD(TIMVAL,NUMVAL,INTGWK) 
CALL VSRTUD(FNCVAL,1,1,NUMVAL,INTGWK.REALWK) 
RETURN 
END 
С 
С > GETPRM : 
С 
С 
SUBROUTINE GETPRM 
С DEURATION 
IMPLICIT REAL*8 (A-H,0-Z) 
LOGICAL*! TERMIO.SMOPER 
CHARACTER*8 ANSWER 
С COMMON 
COMMON /FIPARM/ DLTTIM.ENDTIM.NUMELM.NUMSPL.NUMEXT 
COMMON /SYSUSE/ lERR.LNITRM.LNOTRM.LNERRO, 
1 LNOFNC.LNTFNC.LNIFNC,TERMIO.SMOPER 
С 
10 CONTINUE 
IERR=0 
С GET DELTA-T 
CALL CLEAR 
WRITE(LN0TRM,1000) 
READ(LNITRM,*,END=20) DLTTIM 
IF (DLTTIM .GT. O.ODO) THEN 
GO TO 30 
20 CONTINUE 
CALL ERRHND 
GO TO 10 
30 CONTINUE 
С GET ENDTIME 
CALL CLEAR 
WRITE(LN0TRM,1010) 
READ(LNITRM,*,END=40) ENDTIM 
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С CALCULATE TOTAL NUMBER OF ELEMENTS 
NUMELM=l+(ENDTIM/DLTTIM) 
С CHANGE TO NEAREST POWER OF TWO 
CALL GETPW2(NUMELM) 
С CHANGE ENDTIME TO CORRESPONDING TOTAL NUMBER OF ELEMENTS 
ENDTIM=DLTTIM*(NUMELM-1) 
С MINIMUM 4 (SPLINE OPERATION), MAXIMUM 1024 (STORAGE DECLARATION) 
IF (NUMELM .LE. 1024 .AND. NUMELM .GT. 4) THEN 
GO TO 50 
ENDIF 
CALL ERRHND 
GO TO 10 
40 CONTINUE 
CALL ERRHND 
GO TO 30 
50 CONTINUE 
С SMOOTHING OPERATION ? 
CALL CLEAR 
WRITE(LNOTRM,1020) 
READ(LNITRM,1030,END=60) ANSWER 
IF (ANSWER .EQ. 'YES') THEN 
С SMOOTHING INVOKED 
SMOPER=.TRUE. 
ELSE IF (ANSWER .EQ. 'NO') THEN 
С SMOOTHING NOT INVOKED 
SMOPER=.FALSE. 
ELSE 
60 CONTINUE 
CALL ERRHND 
GO TO 50 
END IF 
END IF 
CALL CLEAR 
RETURN 
С 
1000 FORMATC FOR INTERPOLATION : ENTER THE DELTA-T') 
1010 FORMATC FOR EXTRAPOLATION : ENTER THE ENDTIME') 
1020 FORMATC DATA MUST BE SMOOTHED ? : ENTER YES OR NO') 
1030 F0RMAT(A8) 
END 
С 
С > GETPW2 : 
С 
С 
SUBROUTINE GETPW2(N) 
С DECLARATION 
IMPLICIT REAL*8 (A-H,0-Z) 
С 
DO 10 І=0^ 
С POWER OF TWO 
M=2**I 
IF (N .LE. M) THEN 
С SET DUMMY ARGUMENT TO POWER OF TWO 
N=M 
RETURN 
END IF 
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10 CONTINUE 
N=0 
RETURN 
END 
С 
С > PREPAR : 
С 
С 
SUBROUTINE PREPAR(TIMVAL,FNCVAL,NUMVAL,CMPBUF) 
С DECLARATION 
IMPLICIT REAL*8 (Α-Η,Ο-2) 
LOGICAL*! TERMIO.SMOPER 
C0MPLEX*16 CMPBUF 
DIMENSION TIMVAL(NUMVAL),FNCVAL(NUMVAL),CMPBUF(NUMELM) 
С COMMON 
COMMON /FIPARM/ DLTTIM.ENDTIM.NUMELM.NUMSPL.NUMEXT 
COMMON /SYSUSE/ IERR,LNITRM,LN0TRM,LNERRO, 
1 LNOFNC, LNTFNC, LNIFNC JERMIO, SMOPER 
С 
С SORT FILE FOR ASCENDING TIMEVALUES 
CALL SRTFIL(TIMVAL,FNCVAL,NUMVAL) 
С NUMBER OF ELEMENTS IN THE FUNCTION AFTER SPLINING 
С WITHOUT THE EXTRAPOLATED PART 
NUMSPL=1+(TIMVAL(NUMVAL)/DLTTIM) 
С NUMBER OF ELEMENTS IN THE EXTRAPOLATED PART 
NUMEXT=NUMELM-NUMSPL 
С IF ENDTIME IS SMALLER THAN THE LAST OBSERVATION TIME 
С NO EXTRAPOLATION IS TO BE PERFORMED 
IF (NUMEXT .GT. 0) THEN 
CALL EXTEND(TIMVAL,FNCVAL,NUMVAL) 
END IF 
С CUBIC SPLINE INTERPOLATION 
CALL SPLINE(TIMVAL,FNCVAL,NUMVAL) 
IF (IERR .NE. 0) THEN 
RETURN 
END IF 
С TRANSFORMATION TO THE FREQUENCY DOMAIN 
CALL TRFRECKTIMVAL,FNCVAL,NUMVAL,CMPBUF) 
IF (IERR .NE. 0) THEN 
RETURN 
END IF 
RETURN 
END 
С 
С > DIVIDE : 
С 
С 
SUBROUTINE DIVIDE 
С DECLARATION 
IMPLICIT REAL*8 (A-H.O-Z) 
LOGICAL*! TERMIO.SMOPER.DVDCHK 
C0MPLEX*16 CMPLWK.FRQOUT.FRQTRP.FRQINP 
С COMMON 
COMMON /FIPARM/ DLTTIM,ENDTIM,NUMELM,NUMSPL,NUMEXT 
COMMON /FIDATA/ TIMOUT(1024),FNCOUT(1024), 
1 TIMTRP(1024),FNCTRP(1024), 
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2 TIMINP(1024),FNCINP(1024), 
3 NUMOUT.NUMTRP.NUMINP 
COMMON /WORK/ CMPLWK(1),FRQOUT(1024),FRQTRP(1024),FRQINP(1024), 
1 REALWK(6294),INTGWK(6294) 
COMMON /SYSUSE/ IERR,LNITRM,LNOTRM,LNERRO, 
1 LNOFNC,LNTFNC,LNIFNC,TERMIO,SMOPER 
С 
С DECONVOLUTION IS DIVISION IN THE FREQUENCY DOMAIN 
DVDCHK=.FALSE. 
DO IO IVAL=1,NUMELM 
С CHECK FOR DIVISION ERROR 
IF (CDABS(FRQTRP(IVAL)) .GT. l.OD-10) THEN 
FRQINP(IVAL)=FRQOUT(IVAL)/FRQTRP(IVAL) 
INTGWK(IVAL)=0 
С FIRST AND U S T ELEMENTS MAY NOT BE IN ERROR 
ELSE IF (IVAL .EQ. 1 .OR. IVAL .EQ. NUMELM) THEN 
IERR=8 
CALL ERRMSG 
ELSE 
С STORE LOCATION TO BE INTERPOLATED 
INTGWK(IVAL)=1 
DVDCHK=.TRUE. 
END IF 
10 CONTINUE 
С RETURN IF EVERYTHING ОКЕ 
IF (.NOT. DVDCHK) THEN 
RETURN 
С ELSE PERFORM INTERPOLATION 
ELSE 
DO 20 IVAL=1,NUMELM 
IF (INTGWK(IVAL) .EQ. 0) THEN 
GO TO 20 
С LINEAR INTERPOLATION 
ELSE 
FRQINP(IVAL)=0.5D0*(FRQINP(IVAL-1)+FRQINP(IVAL+1)) 
ENDIF 
20 CONTINUE 
RETURN 
END IF 
END 
С 
С > TRTIME : 
С 
С 
SUBROUTINE TRTIME 
С DECLARATION 
IMPLICIT REAL*8 (A-H.O-Z) 
C0MPLEX*16 CMPLWK.FRQOUT.FRQTRP.FRQINP 
С COMMON 
COMMON /FIDATA/ TIMOUT(1024),FNCOUT(1024), 
1 TIMTRP(1024),FNCTRP(1024), 
2 TIMINP(1024),FNCINP(1024), 
3 NUMOUT.NUMTRP.NUMINP 
COMMON /FIPARM/ DLTTIM.ENDTIM,NUMELM,NUMSPL.NUMEXT 
COMMON /WORK/ CMPLWK(1),FRQ0UT(1024),FRqTRP(1024),FRQINP(1024), 
1 REALWK(6294),INTGWK(6294) 
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RCPDLT=1.0D0/DLTTIM 
CALL FFTSDÍFRQINP.NUMELM.l.NUMELM.l.l.-l.INTGWK.REALWK.CMPLWK) 
DO IO IFILL=1,NUMELM-1 
С NOTE : HALF OELTA-T SHIFT TO THE RIGHT 
TIMINP(IFILL)=DLTTIM*(DFLOAT(IFILL)-0.5D0) 
С CORRECT FOR DELTA-T FACTOR 
FNCINP(IFILL)=RCPDLT*FRQINP(IFILL+1) 
10 CONTINUE 
С FIRST ELEMENT IS ALWAYS ZERO, THUS NOT TAKEN IN ACCOUNT 
NUMINP=NUMELM-1 
RETURN 
END 
С 
С > SPLINE : 
С 
С 
SUBROUTINE SPLINE(TIMVAL,FNCVAL,NUMVAL) 
С DECLARATION 
IMPLICIT REAL*8 (A-H,0-Z) 
LOGICAL*! TERMIO.SMOPER 
C0MPLEX*16 CMPLWK.FRQOUT.FRQTRP.FRQINP 
DIMENSION TIMVAL(NUMVAL)(FNCVAL(NUMVAL) 
DIMENSION TIMSPL(1024),FNCSPL(1024),SPCOEF(1024,3) 
С COMMON 
COMMON /WORK/ CMPLWK(l),FRqOUT(1024)
>
FRQTRP(1024),FRQINP(1024)( 
1 REALWK(6294),INTGWK(6294) 
COMMON /FIPARM/ DLTTIM.ENDTIM.NUMELM.NUMSPL.NUMEXT 
COMMON /SYSUSE/ lERR.LNITRM.LNOTRM.LNERRO, 
1 LNOFNC,LNTFNC,LNIFNC,TERMIO,SMOPER 
С STORAGE SAVINGS 
EQUIVALENCE (REALWK(l),TIMSPL(1)) 
EQUIVALENCE (REALWK(1025),FNCSPL(1)) 
EQUIVALENCE (REALWK(2049),SPCOEF(1,1)) 
С 
CALL IQHSCUÍTIMVAL.FNCVAL.NUMVAL.SPCOEF,1024,1ER) 
IF (1ER .NE. 0) THEN 
IERR=IER 
RETURN 
END IF 
С GET TIME VALUES FOR INPUT-FUNCTION 
DO 10 IFILL=11NUMELM 
TIMSPL(IFILL)=DLTTIM*(IFILL-1) 
10 CONTINUE 
CALL ICSEVU(TIMVAL)FNCVAL>NUMVAL1SPCOEF,1024, 
1 TIMSPL.FNCSPL.NUMELM.IER) 
IF (1ER .NE. 0) THEN 
IERR=IER 
RETURN 
END IF 
С COPY CALCULATED VALUES FOR INPUT-FUNCTION 
DO 20 IFILL=1,NUMELM 
TIMVAL(IFILL)=TIMSPL(IFILL) 
FNCVAL(IFILL)=FNCSPL(IFILL) 
20 CONTINUE 
NUMVAL=NUMELM 
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RETURN 
END 
С 
С > SMOOTH : 
С 
С 
SUBROUTINE SMOOTH 
С DECLARATION 
IMPLICIT REAL*8 (A-H,0-Z) 
LOGICAL*! TERMIO.SMOPER 
COMPLEX*16 CMPLWK.FRQOUT.FRQTRP.FRQINP 
DIMENSION TIMSPL(1024),FNCSPL(1024),SMWORK(12288) 
DIMENSION TIMKNOÍShSPVECTtBbSPCOEFCS.S) 
С COMMON 
COMMON /WORK/ CMPLWK(1),FRQ0UT(1024),FRQTRP(1024),FRQINP(1024), 
1 REALWK(6294),INTGWK(6294) 
COMMON /FIPARM/ DLTTIM.ENDTIM.NUMELM.NUMSPL.NUMEXT 
COMMON /FIDATA/ TIMOUT(1024),FNCOUT(1024), 
1 TIMTRP(1024),FNCTRP(1024), 
2 TIMINP(1024))FNCINP(1024), 
3 NUMOUT.NUMTRP.NUMINP 
COMMON /SYSUSE/ lERR.LNITRM.LNOTRM.LNERRO, 
1 LNOFNC.LNTFNC.LNIFNC,TERMIO.SMOPER 
С STORAGE SAVINGS 
EQUIVALENCE (CMPLWK(l),SMW0RK(1)) 
EQUIVALENCE (INTGWK(l),TIMSPL(1)) 
EQUIVALENCE (INTGWK(2049),FNCSPL(1)) 
EQUIVALENCE (INTGWK(4097),TIMKN0(1)) 
EQUIVALENCE (INTGWK(4109),SPVECT(1)) 
EQUIVALENCE (INTGWK(4119),SPCOEF(1,1)) 
С 
С SMOOTHING TO BE INVOKED ? 
IF (.NOT. SMOPER) RETURN 
С NOTE : NO MORE THAN 6 KNOTS, ELSE STORAGE OVERFLOWS 
NUMKN0=6 
TIMKN0(1)=0.0D0 
TIMKN0(2)=TIMINP(NUMSPL/16) 
TIMKN0(3)=TIMINP(NUMSPL/8) 
TIMKN0(4)=TIMINP(NUMSPL/4) 
TIMKNO(5)=TIMINP(NUMSPL/2) 
T1MKN0(6)=TIMINP(NUMINP) 
С VARIABLE KNOT LOCATION SMOOTHER 
CALL ICSVKU(TIMINP,FNCINP,NUMINP,TIMKNO,NUMKNO, 
1 SPVECT, SPCOEF,1024,ERRLSQ,SMWORK
>
IER) 
IF (1ER .NE. 0) THEN 
IERR=7 
CALL ERRMSG 
RETURN 
END IF 
С GET TIME VALUES FOR INPUT-FUNCTION 
TIMSPL(1)=0.0D0 
DO 20 IFILL=2,NUMINP 
TIMSPL(IFILL)=DLTTIM*(IFILL-1) 
20 CONTINUE 
CALL ICSEVU(TIMKNO,SPVECT)NUMKN0)SPCOEF,1024, 
1 TIMSPL.FNCSPL.NUMINP.IER) 
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IF (1ER .NE. 0) THEN 
IERR=7 
CALL ERRMSG 
RETURN 
END IF 
С COPY CALCULATED VALUES FOR INPUT-FUNCTION 
DO 30 IFILL=1,NUMINP 
TIMINP(IFILL)=TIMSPL(IFILL) 
FNCINP(IFILL)=FNCSPL( IFILL) 
30 CONTINUE 
RETURN 
END 
С 
С > EXTEND : 
С 
С 
SUBROUTINE EXTEND(TIMVAL,FNCVAL,NUMVAL) 
С DECLARATION 
IMPLICIT REAL*8 (A-H,0-Z) 
LOGICAL*! TERMIO.SMOPER 
C0MPLEX*16 CMPLWK.FRQOUT.FRQTRP.FRQINP 
DIMENSION TIMVAL(NUMVAL),FNCVAL(NUMVAL) 
DIMENSION TIMEXT(1024),FNCEXT(1024) 
С COMMON 
COMMON /WORK/ CMPLWK(l),FRQOUT(1024),FRQTRP(1024),FRQINPC1024), 
1 REALWK(6294),INTGWK(6294) 
COMMON /FIPARM/ DLTTIM,ENDTIM,NUMELM,NUMSPL,NUMEXT 
COMMON /SYSUSE/ IERR,LNITRM,LNOTRM,LNERRO, 
1 LNOFNC,LNTFNC,LNIFNC,TERMIO,SMOPER 
С STORAGE SAVINGS 
EQUIVALENCE (REALWK(1),TIMEXT(1)) 
EQUIVALENCE (REALWK(1025),FNCEXT(1)) 
С 
IFILL=0 
С EXTRAPOLATION IS PERFORMED USING LAST 4 ELEMENTS OF ORIGINAL FUNCTION 
DO 10 IGET=NUMVAL-3,NUMVAL 
С VALUE MUST BE POSITIVE TO TAKE THE LOGARITHM 
IF (FNCVAL(IGET) .GT. O.ODO) THEN 
IFILL=IFILL+1 
TIMEXT(IFILL)=TIMVAL(IGET) 
FNCEXT(I FILL)=DLOG(FNCVAL(IGET)) 
С ELSE EXTEND WITH VALUE ZERO 
ELSE 
GO TO 30 
END IF 
10 CONTINUE 
С GET SLOPE AND INTERCEPT OF LOG-LINE 
CALL LSTSQR(TIMEXT,FNCEXT,4,SL0PE,CEPT) 
DO 20 IFILL=NUMVAL+1,NUMVAL+NUMEXT 
С AND CALCULATE THE EXTRAPOLATION PART 
TIMVAL(IFILL)=DLTTIM*(NUMSPL+IFILL-NUMVAL) 
FNCVAL(IFILL)=DEXP(SLOPE*TIMVAL(IFILL)+CEPT) 
20 CONTINUE 
NUMVAL=NUMVAL+NUMEXT 
RETURN 
30 CONTINUE 
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С SET THE EXTRAPOLATION PART TO ZERO 
DO 40 IFILL=NUMVAL+1,NUMVAL+NUMEXT 
TIMVAL(IFILL)=DLTTIM*(NUMSPL+IFILL-NUMVAL) 
FNCVAL(IFILL)=0-ODO 
40 CONTINUE 
NUMVAL=NUMVAL+NUMEXT 
RETURN 
END 
С 
С > LSTSQR : 
С 
С 
SUBROUTINE LSTSQRCX.Y.N.SLOPE.CEPT) 
С DECLARATION 
IMPLICIT REAL*8 (A-H.O-Z) 
DIMENSION X(N),Y(N) 
С 
С LEAST-SQUARES LINEAR APPROXIMATION 
SUMX=0.0D0 
SUMY=0.0D0 
SUMX2=0.0D0 
SUMXY=0.0D0 
DO 10 1=1,N 
SUMX=SUMX+X(I) 
SUMY=SUMY+Y(I) 
SUMX2=SUMX2+(X(I))**2 
SUMXY=SUMXY+X(I)*Y(I) 
10 CONTINUE 
С CALCULATE NUMERATOR 
C=1.0D0/((DFLOAT(N)*SUMX2)-(SUMX)**2) 
С CALCULATE SLOPE OF LINE 
SLOPE=((DFLOAT(N)*SUMXY)-(SUMX*SUMY))*C 
С CALCULATE INTERCEPT OF LINE 
CEPT=((SUMX2*SUMY)-(SUMX*SUMXY))*C 
RETURN 
END 
С 
С > TRFREQ : 
С 
С 
SUBROUTINE TRFREQÍTIMVAL.FNCVAL.NUMVAL.CMPBUF) 
С DECLARATION 
IMPLICIT REAL*8 (Α-Η,Ο-Ζ) 
C0MPLEX*16 CMPBUF.CMPLWK.FRQOUT.FRQTRP.FRQINP 
DIMENSION TIMVAL(NUMVAL),FNCVAL(NUMVAL),CMPBUF(NUMVAL) 
С COMMON 
COMMON /WORK/ CMPLWK(1))FRQOUT(1024),FRQTRP(1024),FRQINP(1024)> 
1 REALWK(6294),INTGWK(6294) 
С 
С FILL COMPLEX BUFFER 
DO 10 IFILL=1
>
NUMVAL 
CMPBUF(IFILL)=FNCVAL(IFILL) 
10 CONTINUE 
CALL FFTSDCCMPBUF.NUMVAL.MUMVAL.l.l.l.INTGWK.REALWK.CMPLWK) 
RETURN 
END 
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с 
С > ERRMSG : 
С 
С 
SUBROUTINE ERRMSG 
С DECLARATION 
IMPLICIT REAL*8 (Α-Η,Ο-Ζ) 
LOGICAL*! TERMIO.SMOPER 
COMMON 
COMMON /SYSUSE/ IERR,LNITRM,LNOTRM,LNERRO, 
1 LNOFNC.LNTFNC.LNIFNC,TERMIO.SMOPER 
С 
С JUMP TO SPECIFIC ERROR HANDLING 
GO ТО (1,2,3,4,5,6,7,8),IERR 
С IERR=0 
1 
2 
3 
4 
5 
6 
7 
8 
1000 
1010 
1020 
1030 
1040 
1050 
1060 
1070 
1080 
С 
С — 
С 
С 
WRITE(LNERRO,1000) 
RETURN 
CONTINUE 
WRITE(LNERRO,1010) 
RETURN 
CONTINUE 
WRITE(LNERRO,1020) 
RETURN 
CONTINUE 
WRITE(LNERRO,1030) 
STOP 
CONTINUE 
WRITE(LNERR0,1040) 
STOP 
CONTINUE 
WRITE(LNERRO,1050) 
STOP 
CONTINUE 
WRITE(LNERRO,1060) 
STOP 
CONTINUE 
WRITE(LNERRO,1070) 
RETURN 
CONTINUE 
WRITE(LNERRO,1080) 
STOP 
FORMATC WRONG INPUT, — > RE-ENTER',/) 
FORMATC MAXIMUM REACHED WHILE READING TRANSPORT-FUNCTION DATA') 
FORMATC MAXIMUM REACHED WHILE READING OUTPUT-FUNCTION DATA') 
FORMATC ERROR WHILE PREPARING TRANSPORT-FUNCTION DATA') 
FORMATC ERROR WHILE PREPARING OUTPUT-FUNCTION DATA') 
FORMATC ERROR IN COMPLEX DIVISION') 
FORMATC ILLEGAL PARAMETER-INPUT') 
FORMATC ERROR WHILE SMOOTHING INPUT-FUNCTION DATA') 
FORMATC DIVISION ERROR IN FREQUENCY DOMAIN') 
END 
-> ERRHND : 
SUBROUTINE ERRHND 
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С DECLARATION 
IMPLICIT REAL*8 (Α-Η,Ο-Ζ) 
LOGICAL*! TERMIO.SMOPER 
С COMMON 
COMMON /SYSUSE/ lERR.LNITRM.LNOTRM.LNERRO, 
1 LNOFNC.LNTFNC.LNIFNC,TERMIO.SMOPER 
С 
С IF INTERACTIVE MODE REWIND INPUT-UNIT 
IF (TERMIO) THEN 
REWIND LNITRM 
ELSE 
С IF NOT, STOP FURTHER PROCESSING 
IERR=6 
END IF 
CALL ERRMSG 
RETURN 
END 
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Summary 
In this thesis a different approach is studied solving pharmacological and 
specifically pharmacokinetical problems. Basically, the theory used is avail-
able from general systems theory, whereby systems characteristics can be 
described by its response on a particular input. The main difference between 
the systems approach and the classical compartment model theory, is that the 
latter does make certain assumptions about the properties of a compartment. 
This thesis is composed of four sections, of which all mathematical equations 
used are part of section 4. In section 1, chapter 1, the concept system is 
introduced and its context is related with pharmacokinetics. In systems theory 
three other concepts are mentioned in conjunction : the input function, the 
output or response function and the transport function ; the latter character-
izes the transport properties of a system and is in pharmacology drug and 
individually dependent. If an input and transport function are mathematically 
known, then the corresponding output function can be calculated by a process 
called convolution. On the other hand, if the output function has been deter-
mined and whether the input or transport function is known, the unknown one 
can be calculated using the deconvolution operation. Also in this chapter some 
remarks have been made concerning the transport function of systems composed 
of subsystems. The body itself is a very complex organisation of subsystems 
and its transport properties are discussed using a well-defined input and out-
put site. All drug inputplaces resp. concentration measurements can then be 
related with the corresponding definitions. As a consequence, the total body 
transport function (TBTF) is introduced, which is the transport function of 
the body from the above defined input to the output site. In chapter 2 a 
deconvolution method is proposed of which the computer program source listing 
can be found in chapter 10. Simulation tests have been carried out to validate 
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this method with respect to the noise sensitivity, thereby making use of four 
different mathematical models, each often related with pharmacokinetics. 
Section 2 governs the body transport dependence on the choice of the drug 
input site, of course being different from the input referenceplace. Chapter 3 
handels the mathematical determination of the unknown drug absorption. In 
chapter 4 a special case from the literature has been taken, to point out the 
usefulness of the new approach. Chapter 5 is also an example of the input site 
dependence and it handels experimental results of goats which were given a 
dosage of antipyrine in the liquor. In chapter 6 acrylate experiments on guin-
ea pig skin are discussed. This chapter has been written in cooperation with 
Theo Waegemaekers and it will be published in his thesis too. One of the main 
conclusions drawn in this investigation is the formation of acrylate metabo-
lites in the skin on basis of the acrylate measurements only and using, of 
course, the systems approach. 
Section 3 discusses the output site dependence of the transport function of 
which metabolite formation is good example. Chapter 7 gives a mathematical 
introduction and in chapter 8 experimental results on treating goats with 
nicotine and cotinine are discussed. The dependence of the cotinine transport 
function on the nicotinine presence has been investigated and the conclusion 
was that cotinine may be a good reference for studying the nicotine intake, 
once the exact nicotine dependency of cotinine is determined. 
As a concluding remark it is obvious that the new approach supplies a better 
understanding in pharmacokinetics in complex systems as the body, this often 
in contrast with the compartment model theory. In this way, one is more able 
to work on therapy planning in order to establish a wanted concentration time 
behaviour of a drug in a body. 
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Samenvatting 
In het voor u liggende proefschrift wordt een uiteenzetting gegeven van een 
andere denktrant binnen de farmacologie en in het bijzonder de farmacokine-
tiek. Deze manier van denken en rekenen is afkomstig van de theorie der syste-
men, waarbij de karakteristieken van een systeem beschreven worden aan de hand 
van zijn responsie op bepaalde inputs. Het cruciale verschil met de bekende 
farmacologische compartimenten modeltheorie zit hem in de aanname die deze 
laatstse maakt, betreffende de kenmerken van een compartiment. Bij analyses 
van drug concentratie-tijd curven wordt dan ook altijd gebruik gemaakt van de 
parameters die die kenmerken beschrijven, waarbij vaak de relatie met de fys-
iologische werkelijkheid ver te zoeken is. Verder is meermalen gebleken dat 
jonge artsen die zich wilden gaan verdiepen in de farmacokinetiek, problemen 
ondervonden met de betekenis van de parameters verkregen uit de zgn. comparti-
menten model-fitprocedures, terwijl dat niet het geval was bij de in dit 
onderzoek gehanteerde statistische systeem parameters, welke model onafhankel-
ijk zijn. 
Bij de samenstelling van dit proefschrift is gekozen voor een onderverdeling 
in vier secties, waarvan de laatste onder meer alle gebruikte mathematische 
vergelijkingen bevat. In sectie 1 wordt in hoofdstuk 1 het begrip systeem 
geïntroduceerd en wordt ingegaan op de relatie met de farmacokinetiek. In de 
theorie van systemen zijn de volgende begrippen onlosmakelijk met elkaar ver-
bonden : de inputfunktie, de output- of responsefunktie en de transportfunk-
tie ; deze laatste karakteriseert de transporteigenschappen van een systeem. 
Gegeven een input- en transportfunktie is het mogelijk om de bijbehorende out-
putfunktie te berekenen ; dit wordt convolutie genoemd. Gegeven een output-
funktie, dan is de inputfunktie te berekenen als de transportfunktie bekend is 
of andersom, is de transportfunktie te berekenen als de inputfunktie bekend 
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is ; dit proces wordt deconvolutie genoemd. Vervolgens is ingegaan op 
konbinaties van systemen en wat dan de consequentie is voor de transportfunk-
tie van het samengestelde systeem. Het lichaam is namelijk een voorbeeld van 
een complex samengesteld systeem en voor dit systeem wordt een referentie 
input- en output-zijde gedefinieerd : resp. de vena cava en de aorta. Elke 
drug inputplaats en concentratie meetplaats kan dan hieraan gerelateerd wor-
den. Aan de hand hiervan wordt het begrip total body transport function geïn-
troduceerd (TBTF), wat de transport eigenschappen van het lichaam voor een 
bepaalde drug voorstelt, waarbij een bolus injectie gegeven is in het referen-
tiepunt en de concentratie metingen gedaan zijn in het output referentiepunt. 
In hoofdstuk 2 wordt een deconvolutie berekenings methode voorgesteld, waarvan 
de Fortran programma listing te vinden is in hoofdstuk 10. Verder beschrijft 
dit hoofdstuk de testen die deze methode valideren wat betreft zijn ruisgevoe-
ligheid. Hiervoor zijn vier verschillende mathematische modellen gekozen, 
allen sterk gerelateerd aan modellen binnen de farmacokinetiek. 
Sectie 2 beschrijft de afhankelijkheid van de transport eigenschappen van het 
lichaam bij een andere inputplaats dan het referentiepunt. In hoofdstuk 3 
wordt vermeld hoe in het algemeen hierbij het dan onbekende opnameproces van 
de drug kan worden berekend. Hoofdstuk 4 behandelt een geval uit de literatuur 
om aan te tonen dat de interpretatie van de metingen van meer waarde is dan de 
standaard compartimenten-aanpak. Hoofdstuk 5 is een voorbeeld waarbij de 
inputfunktie berekend is bij geiten behandeld met een dosis antipyrine in de 
liquor. Hoofdstuk 6 is geschreven samen met Theo Waegemaekers en het omvat 
een gedeelte van zijn onderzoek ; dit hoofdstuk zal dan ook in zijn proefs-
chrift verschijnen. Het is gewijd aan metingen aan met acrylaten epi-cutaan 
behandelde cavia's. De belangrijkste konklusie getrokken op grond van farma-
cokinetische gegevens van de acrylaten zelf, is de vorming van metabolieten in 
de huid na epi-cutane toediening van het acrylaat. 
In sectie 3 wordt ingegaan op een speciaal geval van de lichaams systeem-
outputfunktie, namelijk metaboliet vorming. Hoofdstuk 7 geeft hiervan een 
mathematische beschouwing en hoofdstuk 8 behandelt de experimentele resultaten 
van nicotine-cotinine metingen in geiten. Hierbij is onderzocht of de verwerk-
ing van cotinine, enerzijds gevormd als metaboliet van nicotine en anderzijds 
als drug gedoseerd, onderling verschilden. Hieruit is de konklusie getrokken 
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dat het volgen van cotinine gerechtvaardigd is om uitspraken te kunnen doen 
omtrent de nicotine opname, wanneer de invloed van nicotine op de cotinine-
TBTF bekend is. 
Als slotkonklusie kan gesteld worden dat de systeem aanpak zoals deze in dit 
proefschrift wordt voorgesteld, betere inzichten verschaft in de farmacokine-
tische processen in het complexe systeem als dat van het lichaam en dat men 
beter in staat is om drug-doseringsschema1s (en plaatsen) te onderzoeken en 
plannen om een bepaald gewenst concentratieverloop te kunnen bewerkstelligen. 
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Donkwoord 
Dat ik het schrijven van dit gedeelte onderschat heb blijkt pas, nu ik er ges-
talte aan moet geven. Vaak heb ik me voorgesteld, uit gewoonte en gemak, hier 
alle namen te noemen van degenen die op enigerlei wijze betrokken zijn geweest 
bij de totstandkoming van de inhoud van dit proefschrift. Ondanks dat velen 
het als prettig ervaren om hun bijdrage in een boekje genoemd te zien, heeft 
zo'n lijst een paar vervelende nadelen. Het is namelijk een opsomming van 
slechts sommige bewezen diensten van de betreffende personen en veelal hebben 
deze dan ook nog alleen een zakelijk karakter. Verder zou een lijst een hier-
archische weergave zijn van de geleverde bijdrage, hetgeen door mij zeker niet 
als zodanig ervaren hoeft te zijn. Ook is het mogelijk namen vergeten te ver-
melden, wat, vereeuwigd, een doorn in vooral mijn oog zou zijn. 
Vanuit dit standpunt bezien, wil ik aan allen van wie ik in min of meerdere 
mate (werk)tijd gebruikt heb, een blijk van erg veel dank geven en ik hoop dat 
zij, die weten dat het op hen slaat, mij deze houding niet kwalijk zullen 
nemen. 
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in het lichaam ; de resultaten van dit onderzoek zijn beschreven in dit 
proefschrift. 
Sinds juni 1984 is hij werkzaam bij Philips Medical Systems te Best. 
127 

Stellingen 
I 
Voor het testen van de betrouwbaarheid van zijn deconvolutie methode heeft 
Cutler gebruik gemaakt van response-waarden berekend met behulp van numerieke 
convolutie in plaats van de analytische response-waarden, hetgeen leidt tot 
verkeerde interpretaties. 
Cutler DJ, J Pharmacokin Biopharm 6:227-241 
II 
Het klakkeloos Overnemen van de onjuiste gegevens van Cutler door Veng-
Pedersen, leidt tot verkeerde interpretaties betreffende de ruisgevoeligheid 
van zijn deconvolutie methode. 
Veng Pedersen P, J Pharm Sci 69:305-312 
III 
De berekende functiewaarde op tijdstip t=0 bij numerieke deconvolutie is gel-
ijk aan de linkse limiet in t=0( welke bij aanname van causaliteit gelijk is 
aan 0 ; als functiewaarde op tijdstip t=0 van de berekende transportfunctie of 
inputfunctie is de rechtse limiet in t=0 vaak interessanter. 
Vaughan DP, Dennis M, J Pharm Sci 67:663-665 
IV 
Het halsstarrig handhaven van model-afhankelijke in plaats van model-
onafhankelijke parameters voor de beschrijving van farmacokinetische proces-
sen, getuigt van gebrek aan wetenschappelijk educatief inzicht. 
V 
Stilzwijgend worden computersimulaties van complexe processen frequenter aan-
gewend ter verbetering van het onderhavige model, dan als middel om voorspel-
lingen te kunnen doen omtrent deze processen. 
Wolfram S, Sci. Amer. 251:140-151 
VI 
In hun ijver om met behulp van korrekties de variabiliteit van de biologische-
beschikbaarheidsparameter in te perken, wordt door velen er vaak ten onrechte 
vanuit gegaan, dat het verschil in totale plasma klaring tussen het intrave-
neuze en absorptie experiment niet van systematische aard zou kunnen zijn. 
Gibaldi M, Perrier D, in : Pharmacokinetics, New York (1975) 
VII 
De beschrijving van plasma concentratie curven met behulp van exponentiele 
termen, kan niet ongestraft gerelateerd worden aan fysiologische compartimen-
ten. 
dit proefschrift 
VIII 
De uitdrukking "met een aan zekerheid grenzende waarschijnlijkheid" getuigt 
van gebrek aan kennis van de beginselen der statistiek. 
IX 
In sommige universitaire onderzoeksgroepen ontbreekt het aan bedrijfigheid. 
X 
De afkortings methodieken van sommige tekstverwerkerprogramma's dienen te wor-
den herzien. 
XI 
Vanwege het vaak voortijdig afbreken van een universitaire promotieplaats door 
jonge promovendi ten gunste van een vaste aanstelling elders dient, naast het 
begrip parkeerstudie, het begrip parkeerbaan te worden ingevoerd. 

